The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.
Article Details
- CitationCopy to clipboard
Abeltino M, Bonomini S, Bolzoni M, Storti P, Colla S, Todoerti K, Agnelli L, Neri A, Rizzoli V, Giuliani N
The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.
Exp Hematol. 2011 Jan;39(1):55-65. doi: 10.1016/j.exphem.2010.10.005. Epub 2010 Oct 25.
- PubMed ID
- 20977926 [ View in PubMed]
- Abstract
OBJECTIVE: Multiple myeloma (MM) cells are extremely resistant to drug-induced apoptosis due to both intrinsic- and bone marrow (BM) microenvironment-dependent drug resistance particularly supported by bone cells. Growing evidence suggest that the osteoclast inhibitor zoledronic acid (ZOL) exerts both indirect and direct anti-tumoral effects, including an in vitro proapoptotic effect on MM cells, although this property has not yet been clearly observed in MM patients. MATERIALS AND METHODS: In this study, we attempt to better define the cytotoxic effect of ZOL on MM cells in order to identify novel drug combinations able to potentiate its proapoptotic effect. RESULTS: Our data shows that ZOL at concentrations ranging from 10 to 100 muM was able to induce MM cell apoptosis overcoming the prosurvival effect of both stromal cells and osteoclasts and independent of the intrinsic bortezomib resistance of MM cells. Interestingly, we found that the capacity of ZOL to induce apoptosis in bortezomib-resistant cells was associated with a downregulation of the proapoptotic molecule myeloid cell leukemia-1. A transcriptional analysis by microarray was also performed to identify genes specifically modulated by ZOL in bortezomib-resistant MM cells. Finally, we show an additive effect of arsenic trioxide on apoptosis when used in combination with ZOL. CONCLUSIONS: Our in vitro data suggest that the use of ZOL at appropriate doses could be explored clinically in bortezomib-resistant MM patients and combined with arsenic trioxide to increase its proapoptotic effect.
DrugBank Data that Cites this Article
- Pharmaco-transcriptomics
Drug Drug Groups Gene Gene ID Change Interaction Chromosome Bortezomib Approved Investigational ABCA2 20 downregulated Bortezomib results in decreased expression of ABCA2 mRNA 9q34.3 Bortezomib Approved Investigational ABCC1 4363 downregulated Bortezomib results in decreased expression of ABCC1 mRNA 16p13.11 Bortezomib Approved Investigational ABCC4 10257 downregulated Bortezomib results in decreased expression of ABCC4 mRNA 13q32.1 Bortezomib Approved Investigational ABHD16A 7920 upregulated Bortezomib results in increased expression of ABHD16A mRNA 6p21.33 Bortezomib Approved Investigational ABHD2 11057 upregulated Bortezomib results in increased expression of ABHD2 mRNA 15q26.1 Bortezomib Approved Investigational ABI1 10006 upregulated Bortezomib results in increased expression of ABI1 mRNA 10p12.1 Bortezomib Approved Investigational ACOT7 11332 downregulated Bortezomib results in decreased expression of ACOT7 mRNA 1p36.31 Bortezomib Approved Investigational ADAM10 102 downregulated Bortezomib results in decreased expression of ADAM10 mRNA 15q21.3 Bortezomib Approved Investigational AFF1 4299 upregulated Bortezomib results in increased expression of AFF1 mRNA 4q21.3-q22.1 Bortezomib Approved Investigational AFF4 27125 upregulated Bortezomib results in increased expression of AFF4 mRNA 5q31.1 Bortezomib Approved Investigational AGK 55750 downregulated Bortezomib results in decreased expression of AGK mRNA 7q34 Bortezomib Approved Investigational AGRN 375790 downregulated Bortezomib results in decreased expression of AGRN mRNA 1p36.33 Bortezomib Approved Investigational AGTPBP1 23287 upregulated Bortezomib results in increased expression of AGTPBP1 mRNA 9q21.33 Bortezomib Approved Investigational AGTRAP 57085 downregulated Bortezomib results in decreased expression of AGTRAP mRNA 1p36.22 Bortezomib Approved Investigational AIFM2 84883 upregulated Bortezomib results in increased expression of AIFM2 mRNA 10q22.1 Bortezomib Approved Investigational AIM2 9447 upregulated Bortezomib results in increased expression of AIM2 mRNA 1q23.1-q23.2 Bortezomib Approved Investigational ALDH18A1 5832 downregulated Bortezomib results in decreased expression of ALDH18A1 mRNA 10q24.1 Bortezomib Approved Investigational ALDH5A1 7915 downregulated Bortezomib results in decreased expression of ALDH5A1 mRNA 6p22.3 Bortezomib Approved Investigational ALDH6A1 4329 downregulated Bortezomib results in decreased expression of ALDH6A1 mRNA 14q24.3 Bortezomib Approved Investigational ANAPC5 51433 downregulated Bortezomib results in decreased expression of ANAPC5 mRNA 12q24.31 Bortezomib Approved Investigational ANKRD9 122416 upregulated Bortezomib results in increased expression of ANKRD9 mRNA 14q32.31 Bortezomib Approved Investigational ANO10 55129 upregulated Bortezomib results in increased expression of ANO10 mRNA 3p22.1-p21.33 Bortezomib Approved Investigational ANXA2P2 304 upregulated Bortezomib results in increased expression of ANXA2P2 mRNA 9p13.3 Bortezomib Approved Investigational AP1S1 1174 downregulated Bortezomib results in decreased expression of AP1S1 mRNA 7q22.1 Bortezomib Approved Investigational AP2A1 160 downregulated Bortezomib results in decreased expression of AP2A1 mRNA 19q13.33 Bortezomib Approved Investigational APOBEC3G 60489 upregulated Bortezomib results in increased expression of APOBEC3G mRNA 22q13.1 Bortezomib Approved Investigational APOBR 55911 downregulated Bortezomib results in decreased expression of APOBR mRNA 16p12.1 Bortezomib Approved Investigational APOL1 8542 upregulated Bortezomib results in increased expression of APOL1 mRNA 22q12.3 Bortezomib Approved Investigational APOL4 80832 downregulated Bortezomib results in decreased expression of APOL4 mRNA 22q12.3 Bortezomib Approved Investigational APOOL 139322 upregulated Bortezomib results in increased expression of APOOL mRNA Xq21.1 Bortezomib Approved Investigational AQP3 360 upregulated Bortezomib results in increased expression of AQP3 mRNA 9p13.3 Bortezomib Approved Investigational ARF6 382 upregulated Bortezomib results in increased expression of ARF6 mRNA 14q21.3 Bortezomib Approved Investigational ARFGAP1 55738 downregulated Bortezomib results in decreased expression of ARFGAP1 mRNA 20q13.33 Bortezomib Approved Investigational ARHGAP1 392 downregulated Bortezomib results in decreased expression of ARHGAP1 mRNA 11p11.2 Bortezomib Approved Investigational ARHGDIA 396 downregulated Bortezomib results in decreased expression of ARHGDIA mRNA 17q25.3 Bortezomib Approved Investigational ARL4C 10123 downregulated Bortezomib results in decreased expression of ARL4C mRNA 2q37.1 Bortezomib Approved Investigational ARL8A 127829 upregulated Bortezomib results in increased expression of ARL8A mRNA 1q32.1 Bortezomib Approved Investigational ARRB1 408 downregulated Bortezomib results in decreased expression of ARRB1 mRNA 11q13.4 Bortezomib Approved Investigational ASAP1 50807 downregulated Bortezomib results in decreased expression of ASAP1 mRNA 8q24.21-q24.22 Bortezomib Approved Investigational ATE1 11101 upregulated Bortezomib results in increased expression of ATE1 mRNA 10q26.13 Bortezomib Approved Investigational ATF2 1386 upregulated Bortezomib results in increased expression of ATF2 mRNA 2q31.1 Bortezomib Approved Investigational ATP1A3 478 downregulated Bortezomib results in decreased expression of ATP1A3 mRNA 19q13.2 Bortezomib Approved Investigational ATP6V0E1 8992 upregulated Bortezomib results in increased expression of ATP6V0E1 mRNA 5q35.1 Bortezomib Approved Investigational B3GNT2 10678 downregulated Bortezomib results in decreased expression of B3GNT2 mRNA 2p15 Bortezomib Approved Investigational B4GALT6 9331 upregulated Bortezomib results in increased expression of B4GALT6 mRNA 18q12.1 Bortezomib Approved Investigational BCL3 602 downregulated Bortezomib results in decreased expression of BCL3 mRNA 19q13.32 Bortezomib Approved Investigational BCL6 604 upregulated Bortezomib results in increased expression of BCL6 mRNA 3q27.3 Bortezomib Approved Investigational BCL7A 605 downregulated Bortezomib results in decreased expression of BCL7A mRNA 12q24.31 Bortezomib Approved Investigational BCR 613 downregulated Bortezomib results in decreased expression of BCR mRNA 22q11.23 Bortezomib Approved Investigational BIRC5 332 downregulated Bortezomib results in decreased expression of BIRC5 mRNA 17q25.3 Bortezomib Approved Investigational BLK 640 downregulated Bortezomib results in decreased expression of BLK mRNA 8p23.1 Bortezomib Approved Investigational BLVRB 645 upregulated Bortezomib results in increased expression of BLVRB mRNA 19q13.2 Bortezomib Approved Investigational BRCC3 79184 downregulated Bortezomib results in decreased expression of BRCC3 mRNA Xq28 Bortezomib Approved Investigational BRF2 55290 upregulated Bortezomib results in increased expression of BRF2 mRNA 8p11.23 Bortezomib Approved Investigational BSDC1 55108 upregulated Bortezomib results in increased expression of BSDC1 mRNA 1p35.1 Bortezomib Approved Investigational CAAP1 79886 upregulated Bortezomib results in increased expression of CAAP1 mRNA 9p21.2 Bortezomib Approved Investigational CAPN15 6650 downregulated Bortezomib results in decreased expression of CAPN15 mRNA 16p13.3 Bortezomib Approved Investigational CBR3 874 upregulated Bortezomib results in increased expression of CBR3 mRNA 21q22.12 Bortezomib Approved Investigational CBX3 11335 upregulated Bortezomib results in increased expression of CBX3 mRNA 7p15.2 Bortezomib Approved Investigational CCDC186 55088 upregulated Bortezomib results in increased expression of CCDC186 mRNA 10q25.3 Bortezomib Approved Investigational CCDC6 8030 downregulated Bortezomib results in decreased expression of CCDC6 mRNA 10q21.2 Bortezomib Approved Investigational CCDC82 79780 upregulated Bortezomib results in increased expression of CCDC82 mRNA 11q21 Bortezomib Approved Investigational CCND2 894 downregulated Bortezomib results in decreased expression of CCND2 mRNA 12p13.32 Bortezomib Approved Investigational CCPG1 9236 upregulated Bortezomib results in increased expression of CCPG1 mRNA 15q21.3 Bortezomib Approved Investigational CD38 952 downregulated Bortezomib results in decreased expression of CD38 mRNA 4p15.32 Bortezomib Approved Investigational CD5 921 downregulated Bortezomib results in decreased expression of CD5 mRNA 11q12.2 Bortezomib Approved Investigational CD69 969 upregulated Bortezomib results in increased expression of CD69 mRNA 12p13.31 Bortezomib Approved Investigational CD79A 973 downregulated Bortezomib results in decreased expression of CD79A mRNA 19q13.2 Bortezomib Approved Investigational CD82 3732 downregulated Bortezomib results in decreased expression of CD82 mRNA 11p11.2 Bortezomib Approved Investigational CD9 928 upregulated Bortezomib results in increased expression of CD9 mRNA 12p13.31 Bortezomib Approved Investigational CDC23 8697 upregulated Bortezomib results in increased expression of CDC23 mRNA 5q31.2 Bortezomib Approved Investigational CDC34 997 upregulated Bortezomib results in increased expression of CDC34 mRNA 19p13.3 Bortezomib Approved Investigational CDC42 998 downregulated Bortezomib results in decreased expression of CDC42 mRNA 1p36.12 Bortezomib Approved Investigational CDC42SE2 56990 downregulated Bortezomib results in decreased expression of CDC42SE2 mRNA 5q31.1 Bortezomib Approved Investigational CDKN1A 1026 upregulated Bortezomib results in increased expression of CDKN1A mRNA 6p21.2 Bortezomib Approved Investigational CENPC 1060 upregulated Bortezomib results in increased expression of CENPC mRNA 4q13.2 Bortezomib Approved Investigational CEP290 80184 upregulated Bortezomib results in increased expression of CEP290 mRNA 12q21.32 Bortezomib Approved Investigational CHD2 1106 upregulated Bortezomib results in increased expression of CHD2 mRNA 15q26.1 Bortezomib Approved Investigational CHFR 55743 downregulated Bortezomib results in decreased expression of CHFR mRNA 12q24.33 Bortezomib Approved Investigational CHST11 50515 downregulated Bortezomib results in decreased expression of CHST11 mRNA 12q23.3 Bortezomib Approved Investigational CHST2 9435 downregulated Bortezomib results in decreased expression of CHST2 mRNA 3q24 Bortezomib Approved Investigational CLEC7A 64581 upregulated Bortezomib results in increased expression of CLEC7A mRNA 12p13.2 Bortezomib Approved Investigational CLIP4 79745 upregulated Bortezomib results in increased expression of CLIP4 mRNA 2p23.2 Bortezomib Approved Investigational CLN6 54982 downregulated Bortezomib results in decreased expression of CLN6 mRNA 15q23 Bortezomib Approved Investigational CLPTM1 1209 downregulated Bortezomib results in decreased expression of CLPTM1 mRNA 19q13.32 Bortezomib Approved Investigational CLU 1191 upregulated Bortezomib results in increased expression of CLU mRNA 8p21.1 Bortezomib Approved Investigational CREM 1390 upregulated Bortezomib results in increased expression of CREM mRNA 10p11.21 Bortezomib Approved Investigational CRIP2 1397 downregulated Bortezomib results in decreased expression of CRIP2 mRNA 14q32.33 Bortezomib Approved Investigational CST7 8530 upregulated Bortezomib results in increased expression of CST7 mRNA 20p11.21 Bortezomib Approved Investigational CT45A5 441521 upregulated Bortezomib results in increased expression of CT45A5 mRNA Xq26.3 Bortezomib Approved Investigational CTBP1-AS2 92070 downregulated Bortezomib results in decreased expression of CTBP1-AS2 mRNA 4p16.3 Bortezomib Approved Investigational CTDSPL2 51496 downregulated Bortezomib results in decreased expression of CTDSPL2 mRNA 15q15.3-q21.1 Bortezomib Approved Investigational CTSD 1509 upregulated Bortezomib results in increased expression of CTSD mRNA 11p15.5 Bortezomib Approved Investigational CWF19L1 55280 downregulated Bortezomib results in decreased expression of CWF19L1 mRNA 10q24.31 Bortezomib Approved Investigational CXCR4 7852 downregulated Bortezomib results in decreased expression of CXCR4 mRNA 2q22.1 Bortezomib Approved Investigational CYB5R1 51706 upregulated Bortezomib results in increased expression of CYB5R1 mRNA 1q32.1 Bortezomib Approved Investigational CYBA 1535 downregulated Bortezomib results in decreased expression of CYBA mRNA 16q24.2 Bortezomib Approved Investigational CYP2U1 113612 upregulated Bortezomib results in increased expression of CYP2U1 mRNA 4q25 Bortezomib Approved Investigational CYTIP 9595 upregulated Bortezomib results in increased expression of CYTIP mRNA 2q24.1 Bortezomib Approved Investigational DAZAP2 9802 downregulated Bortezomib results in decreased expression of DAZAP2 mRNA 12q13.13 Bortezomib Approved Investigational DBN1 1627 upregulated Bortezomib results in increased expression of DBN1 mRNA 5q35.3 Bortezomib Approved Investigational DCAF11 80344 downregulated Bortezomib results in decreased expression of DCAF11 mRNA 14q12 Bortezomib Approved Investigational DCAF13 25879 upregulated Bortezomib results in increased expression of DCAF13 mRNA 8q22.3 Bortezomib Approved Investigational DCPS 28960 downregulated Bortezomib results in decreased expression of DCPS mRNA 11q24.2 Bortezomib Approved Investigational DDX11 1663 downregulated Bortezomib results in decreased expression of DDX11 mRNA 12p11.21 Bortezomib Approved Investigational DEAF1 10522 downregulated Bortezomib results in decreased expression of DEAF1 mRNA 11p15.5 Bortezomib Approved Investigational DEF6 50619 downregulated Bortezomib results in decreased expression of DEF6 mRNA 6p21.31 Bortezomib Approved Investigational DENND4A 10260 upregulated Bortezomib results in increased expression of DENND4A mRNA 15q22.31 Bortezomib Approved Investigational DENND4C 55667 upregulated Bortezomib results in increased expression of DENND4C mRNA 9p22.1 Bortezomib Approved Investigational DGKE 8526 downregulated Bortezomib results in decreased expression of DGKE mRNA 17q22 Bortezomib Approved Investigational DNAAF5 54919 downregulated Bortezomib results in decreased expression of DNAAF5 mRNA 7p22.3 Bortezomib Approved Investigational DNAJC14 85406 downregulated Bortezomib results in decreased expression of DNAJC14 mRNA 12q13.2 Bortezomib Approved Investigational DNAJC4 3338 downregulated Bortezomib results in decreased expression of DNAJC4 mRNA 11q13.1 Bortezomib Approved Investigational DNM2 1785 downregulated Bortezomib results in decreased expression of DNM2 mRNA 19p13.2 Bortezomib Approved Investigational DPY19L4 286148 upregulated Bortezomib results in increased expression of DPY19L4 mRNA 8q22.1 Bortezomib Approved Investigational DUSP15 128853 downregulated Bortezomib results in decreased expression of DUSP15 mRNA 20q11.21 Bortezomib Approved Investigational DUSP4 1846 downregulated Bortezomib results in decreased expression of DUSP4 mRNA 8p12 Bortezomib Approved Investigational DYNC1I1 1780 upregulated Bortezomib results in increased expression of DYNC1I1 mRNA 7q21.3 Bortezomib Approved Investigational EHMT2 10919 downregulated Bortezomib results in decreased expression of EHMT2 mRNA 6p21.33 Bortezomib Approved Investigational EIF1 10209 upregulated Bortezomib results in increased expression of EIF1 mRNA 17q21.2 Bortezomib Approved Investigational EIF2S3 1968 downregulated Bortezomib results in decreased expression of EIF2S3 mRNA Xp22.11 Bortezomib Approved Investigational EIF5A 1984 downregulated Bortezomib results in decreased expression of EIF5A mRNA 17p13.1 Bortezomib Approved Investigational ELP5 23587 downregulated Bortezomib results in decreased expression of ELP5 mRNA 17p13.1 Bortezomib Approved Investigational ENO2 2026 upregulated Bortezomib results in increased expression of ENO2 mRNA 12p13.31 Bortezomib Approved Investigational EPHA1 2041 downregulated Bortezomib results in decreased expression of EPHA1 mRNA 7q34-q35 Bortezomib Approved Investigational EPHB2 2048 downregulated Bortezomib results in decreased expression of EPHB2 mRNA 1p36.12 Bortezomib Approved Investigational ERLIN2 11160 downregulated Bortezomib results in decreased expression of ERLIN2 mRNA 8p11.23 Bortezomib Approved Investigational ESF1 51575 upregulated Bortezomib results in increased expression of ESF1 mRNA 20p12.1 Bortezomib Approved Investigational ESRRA 2101 downregulated Bortezomib results in decreased expression of ESRRA mRNA 11q13.1 Bortezomib Approved Investigational ESYT2 57488 downregulated Bortezomib results in decreased expression of ESYT2 mRNA 7q36.3 Bortezomib Approved Investigational ETV4 2118 downregulated Bortezomib results in decreased expression of ETV4 mRNA 17q21.31 Bortezomib Approved Investigational F2RL1 2150 downregulated Bortezomib results in decreased expression of F2RL1 mRNA 5q13.3 Bortezomib Approved Investigational FADS2 9415 downregulated Bortezomib results in decreased expression of FADS2 mRNA 11q12.2 Bortezomib Approved Investigational FAM118B 79607 upregulated Bortezomib results in increased expression of FAM118B mRNA 11q24.2 Bortezomib Approved Investigational FAM168A 23201 upregulated Bortezomib results in increased expression of FAM168A mRNA 11q13.4 Bortezomib Approved Investigational FAM208B 54906 downregulated Bortezomib results in decreased expression of FAM208B mRNA 10p15.1 Bortezomib Approved Investigational FAM20B 9917 downregulated Bortezomib results in decreased expression of FAM20B mRNA 1q25.2 Bortezomib Approved Investigational FAM219A 203259 upregulated Bortezomib results in increased expression of FAM219A mRNA 9p13.3 Bortezomib Approved Investigational FAM43A 131583 downregulated Bortezomib results in decreased expression of FAM43A mRNA 3q29 Bortezomib Approved Investigational FAM76A 199870 upregulated Bortezomib results in increased expression of FAM76A mRNA 1p35.3 Bortezomib Approved Investigational FAM86C1 55199 downregulated Bortezomib results in decreased expression of FAM86C1 mRNA 11q13.4 Bortezomib Approved Investigational FARSA 2193 downregulated Bortezomib results in decreased expression of FARSA mRNA 19p13.13 Bortezomib Approved Investigational FASTK 10922 downregulated Bortezomib results in decreased expression of FASTK mRNA 7q36.1 Bortezomib Approved Investigational FBLN5 10516 downregulated Bortezomib results in decreased expression of FBLN5 mRNA 14q32.12 Bortezomib Approved Investigational FBXW7 55294 downregulated Bortezomib results in decreased expression of FBXW7 mRNA 4q31.3 Bortezomib Approved Investigational FGFR1OP2 26127 upregulated Bortezomib results in increased expression of FGFR1OP2 mRNA 12p11.23 Bortezomib Approved Investigational FKBP1A 2280 downregulated Bortezomib results in decreased expression of FKBP1A mRNA 20p13 Bortezomib Approved Investigational FKBP5 2289 downregulated Bortezomib results in decreased expression of FKBP5 mRNA 6p21.31 Bortezomib Approved Investigational FLCN 201163 upregulated Bortezomib results in increased expression of FLCN mRNA 17p11.2 Bortezomib Approved Investigational FOLR1 2348 downregulated Bortezomib results in decreased expression of FOLR1 mRNA 11q13.4 Bortezomib Approved Investigational FRY 10129 upregulated Bortezomib results in increased expression of FRY mRNA 13q13.1 Bortezomib Approved Investigational FSD1L 83856 upregulated Bortezomib results in increased expression of FSD1L mRNA 9q31.2 Bortezomib Approved Investigational G6PD 2539 downregulated Bortezomib results in decreased expression of G6PD mRNA Xq28 Bortezomib Approved Investigational GABARAPL1 23710 upregulated Bortezomib results in increased expression of GABARAPL1 mRNA 12p13.2 Bortezomib Approved Investigational GADD45A 1647 upregulated Bortezomib results in increased expression of GADD45A mRNA 1p31.3 Bortezomib Approved Investigational GALNT4 8693 upregulated Bortezomib results in increased expression of GALNT4 mRNA 12q21.33 Bortezomib Approved Investigational GANAB 23193 downregulated Bortezomib results in decreased expression of GANAB mRNA 11q12.3 Bortezomib Approved Investigational GAS7 8522 downregulated Bortezomib results in decreased expression of GAS7 mRNA 17p13.1 Bortezomib Approved Investigational GBP2 2634 upregulated Bortezomib results in increased expression of GBP2 mRNA 1p22.2 Bortezomib Approved Investigational GCNT2 2651 upregulated Bortezomib results in increased expression of GCNT2 mRNA 6p24.3-p24.2 Bortezomib Approved Investigational GIT1 28964 downregulated Bortezomib results in decreased expression of GIT1 mRNA 17q11.2 Bortezomib Approved Investigational GKAP1 80318 upregulated Bortezomib results in increased expression of GKAP1 mRNA 9q21.32 Bortezomib Approved Investigational GLA 2717 upregulated Bortezomib results in increased expression of GLA mRNA Xq22.1 Bortezomib Approved Investigational GNAI3 2773 upregulated Bortezomib results in increased expression of GNAI3 mRNA 1p13.3 Bortezomib Approved Investigational GOSR2 9570 upregulated Bortezomib results in increased expression of GOSR2 mRNA 17q21.32 Bortezomib Approved Investigational GPANK1 7918 upregulated Bortezomib results in increased expression of GPANK1 mRNA 6p21.33 Bortezomib Approved Investigational GPAT3 84803 upregulated Bortezomib results in increased expression of GPAT3 mRNA 4q21.23 Bortezomib Approved Investigational GPATCH2L 55668 upregulated Bortezomib results in increased expression of GPATCH2L mRNA 14q24.3 Bortezomib Approved Investigational GPHN 10243 downregulated Bortezomib results in decreased expression of GPHN mRNA 14q23.3 Bortezomib Approved Investigational GPR157 80045 downregulated Bortezomib results in decreased expression of GPR157 mRNA 1p36.22 Bortezomib Approved Investigational GPSM3 63940 downregulated Bortezomib results in decreased expression of GPSM3 mRNA 6p21.32 Bortezomib Approved Investigational GSPT1 2935 downregulated Bortezomib results in decreased expression of GSPT1 mRNA 16p13.13 Bortezomib Approved Investigational GSR 2936 upregulated Bortezomib results in increased expression of GSR mRNA 8p12 Bortezomib Approved Investigational GSTCD 79807 downregulated Bortezomib results in decreased expression of GSTCD mRNA 4q24 Bortezomib Approved Investigational GSTM4 2948 downregulated Bortezomib results in decreased expression of GSTM4 mRNA 1p13.3 Bortezomib Approved Investigational GTF3C2 2976 downregulated Bortezomib results in decreased expression of GTF3C2 mRNA 2p23.3 Bortezomib Approved Investigational GTPBP1 9567 downregulated Bortezomib results in decreased expression of GTPBP1 mRNA 22q13.1 Bortezomib Approved Investigational GZMA 3001 downregulated Bortezomib results in decreased expression of GZMA mRNA 5q11.2 Bortezomib Approved Investigational GZMB 3002 upregulated Bortezomib results in increased expression of GZMB mRNA 14q12 Bortezomib Approved Investigational H6PD 9563 downregulated Bortezomib results in decreased expression of H6PD mRNA 1p36.22 Bortezomib Approved Investigational HADHA 3030 upregulated Bortezomib results in increased expression of HADHA mRNA 2p23.3 Bortezomib Approved Investigational HAUS6 54801 upregulated Bortezomib results in increased expression of HAUS6 mRNA 9p22.1 Bortezomib Approved Investigational HDAC10 83933 downregulated Bortezomib results in decreased expression of HDAC10 mRNA 22q13.33 Bortezomib Approved Investigational HECTD2 143279 upregulated Bortezomib results in increased expression of HECTD2 mRNA 10q23.32 Bortezomib Approved Investigational HEXDC 284004 downregulated Bortezomib results in decreased expression of HEXDC mRNA 17q25.3 Bortezomib Approved Investigational HKR1 284459 upregulated Bortezomib results in increased expression of HKR1 mRNA 19q13.13 Bortezomib Approved Investigational HLA-DMB 3109 downregulated Bortezomib results in decreased expression of HLA-DMB mRNA 6p21.32 Bortezomib Approved Investigational HLA-DOA 3111 downregulated Bortezomib results in decreased expression of HLA-DOA mRNA 6p21.32 Bortezomib Approved Investigational HLA-DPB1 3115 downregulated Bortezomib results in decreased expression of HLA-DPB1 mRNA 6p21.32 Bortezomib Approved Investigational HLA-DRA 3122 downregulated Bortezomib results in decreased expression of HLA-DRA mRNA 6p21.32 Bortezomib Approved Investigational HNRNPLL 92906 upregulated Bortezomib results in increased expression of HNRNPLL mRNA 2p22.1 Bortezomib Approved Investigational HOXA11 3207 downregulated Bortezomib results in decreased expression of HOXA11 mRNA 7p15.2 Bortezomib Approved Investigational HPS3 84343 downregulated Bortezomib results in decreased expression of HPS3 mRNA 3q24 Bortezomib Approved Investigational HSPA5 3309 upregulated Bortezomib results in increased expression of HSPA5 mRNA 9q33.3 Bortezomib Approved Investigational HSPA6 3310 upregulated Bortezomib results in increased expression of HSPA6 mRNA 1q23.3 Bortezomib Approved Investigational HTR2B 3357 downregulated Bortezomib results in decreased expression of HTR2B mRNA 2q37.1 Bortezomib Approved Investigational IBTK 25998 upregulated Bortezomib results in increased expression of IBTK mRNA 6q14.1 Bortezomib Approved Investigational ICK 22858 upregulated Bortezomib results in increased expression of ICK mRNA 6p12.1 Bortezomib Approved Investigational IDE 3416 upregulated Bortezomib results in increased expression of IDE mRNA 10q23.33 Bortezomib Approved Investigational IFI44 10561 upregulated Bortezomib results in increased expression of IFI44 mRNA 1p31.1 Bortezomib Approved Investigational IFRD2 7866 downregulated Bortezomib results in decreased expression of IFRD2 mRNA 3p21.31 Bortezomib Approved Investigational IGLL1 3543 downregulated Bortezomib results in decreased expression of IGLL1 mRNA 22q11.23 Bortezomib Approved Investigational IKZF1 10320 downregulated Bortezomib results in decreased expression of IKZF1 mRNA 7p12.2 Bortezomib Approved Investigational IL15 3600 upregulated Bortezomib results in increased expression of IL15 mRNA 4q31.21 Bortezomib Approved Investigational INO80B 83444 downregulated Bortezomib results in decreased expression of INO80B mRNA 2p13.1 Bortezomib Approved Investigational IPW 3653 upregulated Bortezomib results in increased expression of IPW mRNA 15q11.2 Bortezomib Approved Investigational IRAK2 3656 upregulated Bortezomib results in increased expression of IRAK2 mRNA 3p25.3 Bortezomib Approved Investigational ISCA1 81689 upregulated Bortezomib results in increased expression of ISCA1 mRNA 9q21.33 Bortezomib Approved Investigational ITGA6 3655 downregulated Bortezomib results in decreased expression of ITGA6 mRNA 2q31.1 Bortezomib Approved Investigational ITGAL 3683 downregulated Bortezomib results in decreased expression of ITGAL mRNA 16p11.2 Bortezomib Approved Investigational ITGB6 3694 upregulated Bortezomib results in increased expression of ITGB6 mRNA 2q24.2 Bortezomib Approved Investigational JAK1 3716 downregulated Bortezomib results in decreased expression of JAK1 mRNA 1p31.3 Bortezomib Approved Investigational JUND 3727 downregulated Bortezomib results in decreased expression of JUND mRNA 19p13.11 Bortezomib Approved Investigational KAT6B 23522 downregulated Bortezomib results in decreased expression of KAT6B mRNA 10q22.2 Bortezomib Approved Investigational KATNAL1 84056 upregulated Bortezomib results in increased expression of KATNAL1 mRNA 13q12.3 Bortezomib Approved Investigational KCMF1 56888 upregulated Bortezomib results in increased expression of KCMF1 mRNA 2p11.2 Bortezomib Approved Investigational KCTD10 83892 upregulated Bortezomib results in increased expression of KCTD10 mRNA 12q24.11 Bortezomib Approved Investigational KDELR1 10945 downregulated Bortezomib results in decreased expression of KDELR1 mRNA 19q13.33 Bortezomib Approved Investigational KDM4B 23030 downregulated Bortezomib results in decreased expression of KDM4B mRNA 19p13.3 Bortezomib Approved Investigational KDM5C 8242 downregulated Bortezomib results in decreased expression of KDM5C mRNA Xp11.22 Bortezomib Approved Investigational KIAA0368 23392 upregulated Bortezomib results in increased expression of KIAA0368 mRNA 9q31.3 Bortezomib Approved Investigational KIF22 3835 downregulated Bortezomib results in decreased expression of KIF22 mRNA 16p11.2 Bortezomib Approved Investigational KIF9 64147 downregulated Bortezomib results in decreased expression of KIF9 mRNA 3p21.31 Bortezomib Approved Investigational KIFC1 3833 downregulated Bortezomib results in decreased expression of KIFC1 mRNA 6p21.32 Bortezomib Approved Investigational KIR2DS3 3808 downregulated Bortezomib results in decreased expression of KIR2DS3 mRNA 19q13.4 alternate reference locus Bortezomib Approved Investigational KIR2DS4 3809 downregulated Bortezomib results in decreased expression of KIR2DS4 mRNA 19q13.42 Bortezomib Approved Investigational KIR3DS1 3813 downregulated Bortezomib results in decreased expression of KIR3DS1 mRNA 19q13.4 alternate reference locus Bortezomib Approved Investigational KLF6 1316 upregulated Bortezomib results in increased expression of KLF6 mRNA 10p15.2 Bortezomib Approved Investigational KLHDC7B 113730 upregulated Bortezomib results in increased expression of KLHDC7B mRNA 22q13.33 Bortezomib Approved Investigational KLHL20 27252 upregulated Bortezomib results in increased expression of KLHL20 mRNA 1q25.1 Bortezomib Approved Investigational KLRK1 22914 downregulated Bortezomib results in decreased expression of KLRK1 mRNA 12p13.2 Bortezomib Approved Investigational KPNA2 3838 upregulated Bortezomib results in increased expression of KPNA2 mRNA 17q24.2 Bortezomib Approved Investigational KRI1 65095 upregulated Bortezomib results in increased expression of KRI1 mRNA 19p13.2 Bortezomib Approved Investigational KRIT1 889 upregulated Bortezomib results in increased expression of KRIT1 mRNA 7q21.2 Bortezomib Approved Investigational KTN1 3895 upregulated Bortezomib results in increased expression of KTN1 mRNA 14q22.1 Bortezomib Approved Investigational LGALS8 3964 upregulated Bortezomib results in increased expression of LGALS8 mRNA 1q43 Bortezomib Approved Investigational LIG4 3981 upregulated Bortezomib results in increased expression of LIG4 mRNA 13q33.3 Bortezomib Approved Investigational LIMA1 51474 upregulated Bortezomib results in increased expression of LIMA1 mRNA 12q13.12 Bortezomib Approved Investigational LIMD1 8994 upregulated Bortezomib results in increased expression of LIMD1 mRNA 3p21.31 Bortezomib Approved Investigational LIMS1 3987 upregulated Bortezomib results in increased expression of LIMS1 mRNA 2q12.3 Bortezomib Approved Investigational LRFN4 78999 downregulated Bortezomib results in decreased expression of LRFN4 mRNA 11q13.1 Bortezomib Approved Investigational LRRC41 10489 downregulated Bortezomib results in decreased expression of LRRC41 mRNA 1p34.1-p33 Bortezomib Approved Investigational LRRFIP1 9208 upregulated Bortezomib results in increased expression of LRRFIP1 mRNA 2q37.3 Bortezomib Approved Investigational LSM4 25804 downregulated Bortezomib results in decreased expression of LSM4 mRNA 19p13.1 Bortezomib Approved Investigational LST1 7940 downregulated Bortezomib results in decreased expression of LST1 mRNA 6p21.33 Bortezomib Approved Investigational LUC7L 55692 upregulated Bortezomib results in increased expression of LUC7L mRNA 16p13.3 Bortezomib Approved Investigational MAFG 4097 upregulated Bortezomib results in increased expression of MAFG mRNA 17q25.3 Bortezomib Approved Investigational MALAT1 378938 upregulated Bortezomib results in increased expression of MALAT1 mRNA 11q13.1 Bortezomib Approved Investigational MAP2K2 5605 downregulated Bortezomib results in decreased expression of MAP2K2 mRNA 19p13.3 Bortezomib Approved Investigational MAP2K6 5608 downregulated Bortezomib results in decreased expression of MAP2K6 mRNA 17q24.3 Bortezomib Approved Investigational MAP4K3 8491 upregulated Bortezomib results in increased expression of MAP4K3 mRNA 2p22.1 Bortezomib Approved Investigational MAP4K4 9448 upregulated Bortezomib results in increased expression of MAP4K4 mRNA 2q11.2 Bortezomib Approved Investigational MAPKAP1 79109 downregulated Bortezomib results in decreased expression of MAPKAP1 mRNA 9q33.3 Bortezomib Approved Investigational MAPKAPK2 9261 downregulated Bortezomib results in decreased expression of MAPKAPK2 mRNA 1q32.1 Bortezomib Approved Investigational MARK2 2011 downregulated Bortezomib results in decreased expression of MARK2 mRNA 11q13.1 Bortezomib Approved Investigational MAZ 4150 downregulated Bortezomib results in decreased expression of MAZ mRNA 16p11.2 Bortezomib Approved Investigational MBD1 4152 downregulated Bortezomib results in decreased expression of MBD1 mRNA 18q21.1 Bortezomib Approved Investigational MBD4 8930 upregulated Bortezomib results in increased expression of MBD4 mRNA 3q21.3 Bortezomib Approved Investigational MBNL1 4154 downregulated Bortezomib results in decreased expression of MBNL1 mRNA 3q25.1-q25.2 Bortezomib Approved Investigational MBP 4155 downregulated Bortezomib results in decreased expression of MBP mRNA 18q23 Bortezomib Approved Investigational MDC1 9656 downregulated Bortezomib results in decreased expression of MDC1 mRNA 6p21.33 Bortezomib Approved Investigational ME1 4199 upregulated Bortezomib results in increased expression of ME1 mRNA 6q14.2 Bortezomib Approved Investigational METTL21A 151194 upregulated Bortezomib results in increased expression of METTL21A mRNA 2q33.3 Bortezomib Approved Investigational MEX3D 399664 downregulated Bortezomib results in decreased expression of MEX3D mRNA 19p13.3 Bortezomib Approved Investigational MFN1 55669 downregulated Bortezomib results in decreased expression of MFN1 mRNA 3q26.33 Bortezomib Approved Investigational MFNG 4242 downregulated Bortezomib results in decreased expression of MFNG mRNA 22q13.1 Bortezomib Approved Investigational MIR21 406991 upregulated Bortezomib results in increased expression of MIR21 mRNA 17q23.1 Bortezomib Approved Investigational MLLT11 10962 upregulated Bortezomib results in increased expression of MLLT11 mRNA 1q21.3 Bortezomib Approved Investigational MORC2 22880 upregulated Bortezomib results in increased expression of MORC2 mRNA 22q12.2 Bortezomib Approved Investigational MRPL19 9801 upregulated Bortezomib results in increased expression of MRPL19 mRNA 2p12 Bortezomib Approved Investigational MRPL30 51263 downregulated Bortezomib results in decreased expression of MRPL30 mRNA 2q11.2 Bortezomib Approved Investigational MRPS12 6183 downregulated Bortezomib results in decreased expression of MRPS12 mRNA 19q13.2 Bortezomib Approved Investigational MRPS5 64969 downregulated Bortezomib results in decreased expression of MRPS5 mRNA 2q11.1 Bortezomib Approved Investigational MTMR6 9107 upregulated Bortezomib results in increased expression of MTMR6 mRNA 13q12.13 Bortezomib Approved Investigational MUC1 4582 downregulated Bortezomib results in decreased expression of MUC1 mRNA 1q22 Bortezomib Approved Investigational MYL12A 10627 upregulated Bortezomib results in increased expression of MYL12A mRNA 18p11.31 Bortezomib Approved Investigational NAB2 4665 downregulated Bortezomib results in decreased expression of NAB2 mRNA 12q13.3 Bortezomib Approved Investigational NABP1 64859 upregulated Bortezomib results in increased expression of NABP1 mRNA 2q32.3 Bortezomib Approved Investigational NADK 65220 downregulated Bortezomib results in decreased expression of NADK mRNA 1p36.33 Bortezomib Approved Investigational NADK2 133686 upregulated Bortezomib results in increased expression of NADK2 mRNA 5p13.2 Bortezomib Approved Investigational NAF1 92345 upregulated Bortezomib results in increased expression of NAF1 mRNA 4q32.2 Bortezomib Approved Investigational NAP1L2 4674 upregulated Bortezomib results in increased expression of NAP1L2 mRNA Xq13.2 Bortezomib Approved Investigational NCF4 4689 downregulated Bortezomib results in decreased expression of NCF4 mRNA 22q12.3 Bortezomib Approved Investigational NCKAP1 10787 upregulated Bortezomib results in increased expression of NCKAP1 mRNA 2q32.1 Bortezomib Approved Investigational NCOA3 8202 upregulated Bortezomib results in increased expression of NCOA3 mRNA 20q13.12 Bortezomib Approved Investigational NDRG1 10397 upregulated Bortezomib results in increased expression of NDRG1 mRNA 8q24.22 Bortezomib Approved Investigational NDRG3 57446 downregulated Bortezomib results in decreased expression of NDRG3 mRNA 20q11.23 Bortezomib Approved Investigational NEAT1 283131 upregulated Bortezomib results in increased expression of NEAT1 mRNA 11q13.1 Bortezomib Approved Investigational NEDD1 121441 upregulated Bortezomib results in increased expression of NEDD1 mRNA 12q23.1 Bortezomib Approved Investigational NETO2 81831 downregulated Bortezomib results in decreased expression of NETO2 mRNA 16q12.1 Bortezomib Approved Investigational NFIA 4774 downregulated Bortezomib results in decreased expression of NFIA mRNA 1p31.3 Bortezomib Approved Investigational NFKBIB 4793 upregulated Bortezomib results in increased expression of NFKBIB mRNA 19q13.1 Bortezomib Approved Investigational NFYC 4802 downregulated Bortezomib results in decreased expression of NFYC mRNA 1p34.2 Bortezomib Approved Investigational NIPSNAP1 8508 downregulated Bortezomib results in decreased expression of NIPSNAP1 mRNA 22q12.2 Bortezomib Approved Investigational NOTCH2 4853 downregulated Bortezomib results in decreased expression of NOTCH2 mRNA 1p12 Bortezomib Approved Investigational NPTX1 4884 downregulated Bortezomib results in decreased expression of NPTX1 mRNA 17q25.3 Bortezomib Approved Investigational NQO1 1728 upregulated Bortezomib results in increased expression of NQO1 mRNA 16q22.1 Bortezomib Approved Investigational NQO2 4835 upregulated Bortezomib results in increased expression of NQO2 mRNA 6p25.2 Bortezomib Approved Investigational NR1H3 10062 downregulated Bortezomib results in decreased expression of NR1H3 mRNA 11p11.2 Bortezomib Approved Investigational NT5C2 22978 upregulated Bortezomib results in increased expression of NT5C2 mRNA 10q24.32-q24.33 Bortezomib Approved Investigational NT5E 4907 downregulated Bortezomib results in decreased expression of NT5E mRNA 6q14.3 Bortezomib Approved Investigational NUB1 51667 upregulated Bortezomib results in increased expression of NUB1 mRNA 7q36.1 Bortezomib Approved Investigational NUCKS1 64710 downregulated Bortezomib results in decreased expression of NUCKS1 mRNA 1q32.1 Bortezomib Approved Investigational NUMB 8650 upregulated Bortezomib results in increased expression of NUMB mRNA 14q24.3 Bortezomib Approved Investigational NUMBL 9253 upregulated Bortezomib results in increased expression of NUMBL mRNA 19q13.2 Bortezomib Approved Investigational NXPE3 91775 upregulated Bortezomib results in increased expression of NXPE3 mRNA 3q12.3 Bortezomib Approved Investigational OBSCN 84033 downregulated Bortezomib results in decreased expression of OBSCN mRNA 1q42.13 Bortezomib Approved Investigational OGDH 4967 downregulated Bortezomib results in decreased expression of OGDH mRNA 7p13 Bortezomib Approved Investigational OGFR 11054 downregulated Bortezomib results in decreased expression of OGFR mRNA 20q13.33 Bortezomib Approved Investigational OGT 8473 downregulated Bortezomib results in decreased expression of OGT mRNA Xq13.1 Bortezomib Approved Investigational ORAI2 80228 downregulated Bortezomib results in decreased expression of ORAI2 mRNA 7q22.1 Bortezomib Approved Investigational OS9 10956 upregulated Bortezomib results in increased expression of OS9 mRNA 12q13.3-q14.1 Bortezomib Approved Investigational OSBPL2 9885 upregulated Bortezomib results in increased expression of OSBPL2 mRNA 20q13.33 Bortezomib Approved Investigational OSGIN1 29948 upregulated Bortezomib results in increased expression of OSGIN1 mRNA 16q23.3 Bortezomib Approved Investigational PACSIN1 29993 upregulated Bortezomib results in increased expression of PACSIN1 mRNA 6p21.3 Bortezomib Approved Investigational PALLD 23022 upregulated Bortezomib results in increased expression of PALLD mRNA 4q32.3 Bortezomib Approved Investigational PANX2 56666 upregulated Bortezomib results in increased expression of PANX2 mRNA 22q13.33 Bortezomib Approved Investigational PAPOLA 10914 downregulated Bortezomib results in decreased expression of PAPOLA mRNA 14q32.2 Bortezomib Approved Investigational PARP6 56965 downregulated Bortezomib results in decreased expression of PARP6 mRNA 15q23 Bortezomib Approved Investigational PATZ1 23598 downregulated Bortezomib results in decreased expression of PATZ1 mRNA 22q12.2 Bortezomib Approved Investigational PBX3 5090 downregulated Bortezomib results in decreased expression of PBX3 mRNA 9q33.3 Bortezomib Approved Investigational PCGF3 10336 upregulated Bortezomib results in increased expression of PCGF3 mRNA 4p16.3 Bortezomib Approved Investigational PCNX4 64430 upregulated Bortezomib results in increased expression of PCNX4 mRNA 14q23.1 Bortezomib Approved Investigational PCYT1A 5130 upregulated Bortezomib results in increased expression of PCYT1A mRNA 3q29 Bortezomib Approved Investigational PDCL 5082 upregulated Bortezomib results in increased expression of PDCL mRNA 9q33.2 Bortezomib Approved Investigational PDE7A 5150 downregulated Bortezomib results in decreased expression of PDE7A mRNA 8q13.1 Bortezomib Approved Investigational PDK2 5164 downregulated Bortezomib results in decreased expression of PDK2 mRNA 17q21.33 Bortezomib Approved Investigational PDXK 8566 upregulated Bortezomib results in increased expression of PDXK mRNA 21q22.3 Bortezomib Approved Investigational PFDN4 5203 upregulated Bortezomib results in increased expression of PFDN4 mRNA 20q13.2 Bortezomib Approved Investigational PHC3 80012 upregulated Bortezomib results in increased expression of PHC3 mRNA 3q26.2 Bortezomib Approved Investigational PHF1 5252 upregulated Bortezomib results in increased expression of PHF1 mRNA 6p21.32 Bortezomib Approved Investigational PHKB 5257 upregulated Bortezomib results in increased expression of PHKB mRNA 16q12.1 Bortezomib Approved Investigational PHLDA1 22822 upregulated Bortezomib results in increased expression of PHLDA1 mRNA 12q15 Bortezomib Approved Investigational PHTF1 10745 upregulated Bortezomib results in increased expression of PHTF1 mRNA 1p13.2 Bortezomib Approved Investigational PI4KB 5298 downregulated Bortezomib results in decreased expression of PI4KB mRNA 1q21.3 Bortezomib Approved Investigational PIP5K1A 8394 downregulated Bortezomib results in decreased expression of PIP5K1A mRNA 1q21.3 Bortezomib Approved Investigational PIR 8544 upregulated Bortezomib results in increased expression of PIR mRNA Xp22.2 Bortezomib Approved Investigational PKIA 5569 upregulated Bortezomib results in increased expression of PKIA mRNA 8q21.13 Bortezomib Approved Investigational PLAA 9373 upregulated Bortezomib results in increased expression of PLAA mRNA 9p21.2 Bortezomib Approved Investigational PLEKHM2 23207 downregulated Bortezomib results in decreased expression of PLEKHM2 mRNA 1p36.21 Bortezomib Approved Investigational PM20D2 135293 upregulated Bortezomib results in increased expression of PM20D2 mRNA 6q15 Bortezomib Approved Investigational PMAIP1 5366 upregulated Bortezomib results in increased expression of PMAIP1 mRNA 18q21.32 Bortezomib Approved Investigational PNISR 25957 upregulated Bortezomib results in increased expression of PNISR mRNA 6q16.2 Bortezomib Approved Investigational PNMT 5409 downregulated Bortezomib results in decreased expression of PNMT mRNA 17q12 Bortezomib Approved Investigational PNO1 56902 upregulated Bortezomib results in increased expression of PNO1 mRNA 2p14 Bortezomib Approved Investigational POC1B 282809 upregulated Bortezomib results in increased expression of POC1B mRNA 12q21.33 Bortezomib Approved Investigational POLM 27434 downregulated Bortezomib results in decreased expression of POLM mRNA 7p13 Bortezomib Approved Investigational POLR3E 55718 upregulated Bortezomib results in increased expression of POLR3E mRNA 16p12.2 Bortezomib Approved Investigational POLR3H 171568 downregulated Bortezomib results in decreased expression of POLR3H mRNA 22q13.2 Bortezomib Approved Investigational PPM1A 5494 upregulated Bortezomib results in increased expression of PPM1A mRNA 14q23.1 Bortezomib Approved Investigational PPM1F 9647 upregulated Bortezomib results in increased expression of PPM1F mRNA 22q11.22 Bortezomib Approved Investigational PPP2R2A 5520 upregulated Bortezomib results in increased expression of PPP2R2A mRNA 8p21.2 Bortezomib Approved Investigational PPP2R5D 5528 downregulated Bortezomib results in decreased expression of PPP2R5D mRNA 6p21.1 Bortezomib Approved Investigational PPP3R1 5534 downregulated Bortezomib results in decreased expression of PPP3R1 mRNA 2p14 Bortezomib Approved Investigational PPP5C 5536 downregulated Bortezomib results in decreased expression of PPP5C mRNA 19q13.32 Bortezomib Approved Investigational PRDM2 7799 downregulated Bortezomib results in decreased expression of PRDM2 mRNA 1p36.21 Bortezomib Approved Investigational PRF1 5551 downregulated Bortezomib results in decreased expression of PRF1 mRNA 10q22.1 Bortezomib Approved Investigational PRKDC 5591 downregulated Bortezomib results in decreased expression of PRKDC mRNA 8q11.21 Bortezomib Approved Investigational PRNP 5621 upregulated Bortezomib results in increased expression of PRNP mRNA 20p13 Bortezomib Approved Investigational PRPF6 24148 downregulated Bortezomib results in decreased expression of PRPF6 mRNA 20q13.33 Bortezomib Approved Investigational PRR7 80758 downregulated Bortezomib results in decreased expression of PRR7 mRNA 5q35.3 Bortezomib Approved Investigational PRSS2 5645 downregulated Bortezomib results in decreased expression of PRSS2 mRNA 7q34 Bortezomib Approved Investigational PSAP 5660 upregulated Bortezomib results in increased expression of PSAP mRNA 10q22.1 Bortezomib Approved Investigational PSEN1 5663 downregulated Bortezomib results in decreased expression of PSEN1 mRNA 14q24.2 Bortezomib Approved Investigational PSMC4 5704 upregulated Bortezomib results in increased expression of PSMC4 mRNA 19q13.11-q13.13 Bortezomib Approved Investigational PSMD12 5718 upregulated Bortezomib results in increased expression of PSMD12 mRNA 17q24.2 Bortezomib Approved Investigational PSMD13 5719 upregulated Bortezomib results in increased expression of PSMD13 mRNA 11p15.5 Bortezomib Approved Investigational PSMD7 5713 upregulated Bortezomib results in increased expression of PSMD7 mRNA 16q23.1 Bortezomib Approved Investigational PSMF1 9491 downregulated Bortezomib results in decreased expression of PSMF1 mRNA 20p13 Bortezomib Approved Investigational PTBP1 5725 downregulated Bortezomib results in decreased expression of PTBP1 mRNA 19p13.3 Bortezomib Approved Investigational PTP4A3 11156 downregulated Bortezomib results in decreased expression of PTP4A3 mRNA 8q24.3 Bortezomib Approved Investigational PTPN11 5781 downregulated Bortezomib results in decreased expression of PTPN11 mRNA 12q24.13 Bortezomib Approved Investigational R3HDM4 91300 downregulated Bortezomib results in decreased expression of R3HDM4 mRNA 19p13.3 Bortezomib Approved Investigational RAB5A 5868 downregulated Bortezomib results in decreased expression of RAB5A mRNA 3p24.3 Bortezomib Approved Investigational RAB8B 51762 downregulated Bortezomib results in decreased expression of RAB8B mRNA 15q22.2 Bortezomib Approved Investigational RAC2 5880 downregulated Bortezomib results in decreased expression of RAC2 mRNA 22q13.1 Bortezomib Approved Investigational RALA 5898 upregulated Bortezomib results in increased expression of RALA mRNA 7p14.1 Bortezomib Approved Investigational RAPGEF1 2889 downregulated Bortezomib results in decreased expression of RAPGEF1 mRNA 9q34.13 Bortezomib Approved Investigational RAPH1 65059 upregulated Bortezomib results in increased expression of RAPH1 mRNA 2q33.2 Bortezomib Approved Investigational RB1CC1 9821 upregulated Bortezomib results in increased expression of RB1CC1 mRNA 8q11.23 Bortezomib Approved Investigational RCAN3 11123 downregulated Bortezomib results in decreased expression of RCAN3 mRNA 1p36.11 Bortezomib Approved Investigational RDH11 51109 upregulated Bortezomib results in increased expression of RDH11 mRNA 14q24.1 Bortezomib Approved Investigational RDH13 112724 upregulated Bortezomib results in increased expression of RDH13 mRNA 19q13.42 Bortezomib Approved Investigational RECQL4 9401 upregulated Bortezomib results in increased expression of RECQL4 mRNA 8q24.3 Bortezomib Approved Investigational RELA 5970 downregulated Bortezomib results in decreased expression of RELA mRNA 11q13.1 Bortezomib Approved Investigational RFFL 117584 upregulated Bortezomib results in increased expression of RFFL mRNA 17q12 Bortezomib Approved Investigational RHOT2 89941 downregulated Bortezomib results in decreased expression of RHOT2 mRNA 16p13.3 Bortezomib Approved Investigational RIT1 6016 upregulated Bortezomib results in increased expression of RIT1 mRNA 1q22 Bortezomib Approved Investigational RNF11 26994 upregulated Bortezomib results in increased expression of RNF11 mRNA 1p32.3 Bortezomib Approved Investigational RNF138 51444 upregulated Bortezomib results in increased expression of RNF138 mRNA 18q12.1 Bortezomib Approved Investigational RNF14 9604 upregulated Bortezomib results in increased expression of RNF14 mRNA 5q31.3 Bortezomib Approved Investigational RNF2 6045 upregulated Bortezomib results in increased expression of RNF2 mRNA 1q25.3 Bortezomib Approved Investigational RPAP3 79657 upregulated Bortezomib results in increased expression of RPAP3 mRNA 12q13.11 Bortezomib Approved Investigational RPL13P5 283345 upregulated Bortezomib results in increased expression of RPL13P5 mRNA 12p13.31 Bortezomib Approved Investigational RPL26 6154 upregulated Bortezomib results in increased expression of RPL26 mRNA 17p13.1 Bortezomib Approved Investigational RPS11 6205 upregulated Bortezomib results in increased expression of RPS11 mRNA 19q13.3 Bortezomib Approved Investigational RPS6KB1 6198 upregulated Bortezomib results in increased expression of RPS6KB1 mRNA 17q23.1 Bortezomib Approved Investigational RPS6KC1 26750 upregulated Bortezomib results in increased expression of RPS6KC1 mRNA 1q32.3 Bortezomib Approved Investigational RRM2B 50484 upregulated Bortezomib results in increased expression of RRM2B mRNA 8q22.3 Bortezomib Approved Investigational RSU1 6251 upregulated Bortezomib results in increased expression of RSU1 mRNA 10p13 Bortezomib Approved Investigational SAFB 6294 downregulated Bortezomib results in decreased expression of SAFB mRNA 19p13.3 Bortezomib Approved Investigational SAMD10 140700 downregulated Bortezomib results in decreased expression of SAMD10 mRNA 20q13.33 Bortezomib Approved Investigational SCARNA17 677769 upregulated Bortezomib results in increased expression of SCARNA17 mRNA 18q21.1 Bortezomib Approved Investigational SCD 6319 downregulated Bortezomib results in decreased expression of SCD mRNA 10q24.31 Bortezomib Approved Investigational SCHIP1 29970 downregulated Bortezomib results in decreased expression of SCHIP1 mRNA 3q25.33 Bortezomib Approved Investigational SCPEP1 59342 upregulated Bortezomib results in increased expression of SCPEP1 mRNA 17q22 Bortezomib Approved Investigational SDHC 6391 downregulated Bortezomib results in decreased expression of SDHC mRNA 1q23.3 Bortezomib Approved Investigational SELENOK 58515 upregulated Bortezomib results in increased expression of SELENOK mRNA 3p21.1 Bortezomib Approved Investigational SENP3 26168 downregulated Bortezomib results in decreased expression of SENP3 mRNA 17p13 Bortezomib Approved Investigational SETD1B 23067 upregulated Bortezomib results in increased expression of SETD1B mRNA 12q24.31 Bortezomib Approved Investigational SFN 2810 upregulated Bortezomib results in increased expression of SFN mRNA 1p36.11 Bortezomib Approved Investigational SFT2D3 84826 downregulated Bortezomib results in decreased expression of SFT2D3 mRNA 2q14.3 Bortezomib Approved Investigational SGK1 6446 upregulated Bortezomib results in increased expression of SGK1 mRNA 6q23.2 Bortezomib Approved Investigational SGMS1 259230 upregulated Bortezomib results in increased expression of SGMS1 mRNA 10q11.23 Bortezomib Approved Investigational SGPP1 81537 upregulated Bortezomib results in increased expression of SGPP1 mRNA 14q23.2 Bortezomib Approved Investigational SGSH 6448 upregulated Bortezomib results in increased expression of SGSH mRNA 17q25.3 Bortezomib Approved Investigational SH2D3C 10044 downregulated Bortezomib results in decreased expression of SH2D3C mRNA 9q34.11 Bortezomib Approved Investigational SH3GLB2 56904 downregulated Bortezomib results in decreased expression of SH3GLB2 mRNA 9q34.11 Bortezomib Approved Investigational SIGMAR1 10280 downregulated Bortezomib results in decreased expression of SIGMAR1 mRNA 9p13.3 Bortezomib Approved Investigational SLC10A7 84068 upregulated Bortezomib results in increased expression of SLC10A7 mRNA 4q31.22 Bortezomib Approved Investigational SLC25A11 8402 downregulated Bortezomib results in decreased expression of SLC25A11 mRNA 17p13.2 Bortezomib Approved Investigational SLC26A11 284129 upregulated Bortezomib results in increased expression of SLC26A11 mRNA 17q25.3 Bortezomib Approved Investigational SLC2A3 6515 upregulated Bortezomib results in increased expression of SLC2A3 mRNA 12p13.31 Bortezomib Approved Investigational SLC35C2 51006 downregulated Bortezomib results in decreased expression of SLC35C2 mRNA 20q13.12 Bortezomib Approved Investigational SLC35G1 159371 downregulated Bortezomib results in decreased expression of SLC35G1 mRNA 10q23.33 Bortezomib Approved Investigational SLC38A6 145389 upregulated Bortezomib results in increased expression of SLC38A6 mRNA 14q23.1 Bortezomib Approved Investigational SLC43A3 29015 downregulated Bortezomib results in decreased expression of SLC43A3 mRNA 11q12.1 Bortezomib Approved Investigational SLC7A5 8140 downregulated Bortezomib results in decreased expression of SLC7A5 mRNA 16q24.2 Bortezomib Approved Investigational SMC1A 8243 downregulated Bortezomib results in decreased expression of SMC1A mRNA Xp11.22 Bortezomib Approved Investigational SMC3 9126 upregulated Bortezomib results in increased expression of SMC3 mRNA 10q25.2 Bortezomib Approved Investigational SMC6 79677 upregulated Bortezomib results in increased expression of SMC6 mRNA 2p24.2 Bortezomib Approved Investigational SMIM11A 54065 downregulated Bortezomib results in decreased expression of SMIM11A mRNA 21q22.11-q22.12 Bortezomib Approved Investigational SMURF2 64750 upregulated Bortezomib results in increased expression of SMURF2 mRNA 17q23.3-q24.1 Bortezomib Approved Investigational SNRNP48 154007 upregulated Bortezomib results in increased expression of SNRNP48 mRNA 6p24.3 Bortezomib Approved Investigational SOCS3 9021 upregulated Bortezomib results in increased expression of SOCS3 mRNA 17q25.3 Bortezomib Approved Investigational SOCS5 9655 upregulated Bortezomib results in increased expression of SOCS5 mRNA 2p21 Bortezomib Approved Investigational SPATA5 166378 upregulated Bortezomib results in increased expression of SPATA5 mRNA 4q28.1 Bortezomib Approved Investigational SPN 6693 downregulated Bortezomib results in decreased expression of SPN mRNA 16p11.2 Bortezomib Approved Investigational SPSB3 90864 upregulated Bortezomib results in increased expression of SPSB3 mRNA 16p13.3 Bortezomib Approved Investigational SPTBN1 6711 upregulated Bortezomib results in increased expression of SPTBN1 mRNA 2p16.2 Bortezomib Approved Investigational SPTY2D1 144108 upregulated Bortezomib results in increased expression of SPTY2D1 mRNA 11p15.1 Bortezomib Approved Investigational SQSTM1 8878 upregulated Bortezomib results in increased expression of SQSTM1 mRNA 5q35.3 Bortezomib Approved Investigational SRRT 51593 downregulated Bortezomib results in decreased expression of SRRT mRNA 7q22.1 Bortezomib Approved Investigational SRSF1 6426 downregulated Bortezomib results in decreased expression of SRSF1 mRNA 17q22 Bortezomib Approved Investigational SSRP1 6749 downregulated Bortezomib results in decreased expression of SSRP1 mRNA 11q12.1 Bortezomib Approved Investigational STIM2 57620 downregulated Bortezomib results in decreased expression of STIM2 mRNA 4p15.2 Bortezomib Approved Investigational STIP1 10963 downregulated Bortezomib results in decreased expression of STIP1 mRNA 11q13.1 Bortezomib Approved Investigational STS 412 downregulated Bortezomib results in decreased expression of STS mRNA Xp22.31 Bortezomib Approved Investigational STX12 23673 upregulated Bortezomib results in increased expression of STX12 mRNA 1p35.3 Bortezomib Approved Investigational STYK1 55359 upregulated Bortezomib results in increased expression of STYK1 mRNA 12p13.2 Bortezomib Approved Investigational SUDS3 64426 upregulated Bortezomib results in increased expression of SUDS3 mRNA 12q24.23 Bortezomib Approved Investigational SUMO1 7341 upregulated Bortezomib results in increased expression of SUMO1 mRNA 2q33.1 Bortezomib Approved Investigational SUSD4 55061 downregulated Bortezomib results in decreased expression of SUSD4 mRNA 1q41 Bortezomib Approved Investigational SVOPL 136306 downregulated Bortezomib results in decreased expression of SVOPL mRNA 7q34 Bortezomib Approved Investigational SYNGR2 9144 downregulated Bortezomib results in decreased expression of SYNGR2 mRNA 17q25.3 Bortezomib Approved Investigational TAGLN2 8407 downregulated Bortezomib results in decreased expression of TAGLN2 mRNA 1q23.2 Bortezomib Approved Investigational TANK 10010 upregulated Bortezomib results in increased expression of TANK mRNA 2q24.2 Bortezomib Approved Investigational TBC1D9 23158 upregulated Bortezomib results in increased expression of TBC1D9 mRNA 4q31.21 Bortezomib Approved Investigational TBCD 6904 downregulated Bortezomib results in decreased expression of TBCD mRNA 17q25.3 Bortezomib Approved Investigational TBL1X 6907 upregulated Bortezomib results in increased expression of TBL1X mRNA Xp22.31-p22.2 Bortezomib Approved Investigational TCF7 6932 downregulated Bortezomib results in decreased expression of TCF7 mRNA 5q31.1 Bortezomib Approved Investigational TFDP1 7027 downregulated Bortezomib results in decreased expression of TFDP1 mRNA 13q34 Bortezomib Approved Investigational THEM6 51337 downregulated Bortezomib results in decreased expression of THEM6 mRNA 8q24.3 Bortezomib Approved Investigational THY1 7070 downregulated Bortezomib results in decreased expression of THY1 mRNA 11q23.3 Bortezomib Approved Investigational TM2D2 83877 upregulated Bortezomib results in increased expression of TM2D2 mRNA 8p11.22 Bortezomib Approved Investigational TM2D3 80213 upregulated Bortezomib results in increased expression of TM2D3 mRNA 15q26.3 Bortezomib Approved Investigational TMEM230 29058 downregulated Bortezomib results in decreased expression of TMEM230 mRNA 20p13-p12.3 Bortezomib Approved Investigational TMEM254 80195 downregulated Bortezomib results in decreased expression of TMEM254 mRNA 10q22.3 Bortezomib Approved Investigational TMEM263 90488 upregulated Bortezomib results in increased expression of TMEM263 mRNA 12q23.3 Bortezomib Approved Investigational TMEM41B 440026 upregulated Bortezomib results in increased expression of TMEM41B mRNA 11p15.4 Bortezomib Approved Investigational TMEM55B 90809 downregulated Bortezomib results in decreased expression of TMEM55B mRNA 14q11.2 Bortezomib Approved Investigational TMEM92 162461 downregulated Bortezomib results in decreased expression of TMEM92 mRNA 17q21.33 Bortezomib Approved Investigational TMPO 7112 downregulated Bortezomib results in decreased expression of TMPO mRNA 12q23.1 Bortezomib Approved Investigational TOR1AIP1 26092 downregulated Bortezomib results in decreased expression of TOR1AIP1 mRNA 1q25.2 Bortezomib Approved Investigational TPI1 7167 upregulated Bortezomib results in increased expression of TPI1 mRNA 12p13.31 Bortezomib Approved Investigational TPM1 7168 upregulated Bortezomib results in increased expression of TPM1 mRNA 15q22.2 Bortezomib Approved Investigational TRA2A 29896 downregulated Bortezomib results in decreased expression of TRA2A mRNA 7p15.3 Bortezomib Approved Investigational TRAFD1 10906 upregulated Bortezomib results in increased expression of TRAFD1 mRNA 12q24.13 Bortezomib Approved Investigational TRIM65 201292 downregulated Bortezomib results in decreased expression of TRIM65 mRNA 17q25.1 Bortezomib Approved Investigational TRIO 7204 downregulated Bortezomib results in decreased expression of TRIO mRNA 5p15.2 Bortezomib Approved Investigational TRRAP 8295 downregulated Bortezomib results in decreased expression of TRRAP mRNA 7q22.1 Bortezomib Approved Investigational TSEN15 116461 downregulated Bortezomib results in decreased expression of TSEN15 mRNA 1q25.3 Bortezomib Approved Investigational TTC39A 22996 upregulated Bortezomib results in increased expression of TTC39A mRNA 1p32.3 Bortezomib Approved Investigational TTC7A 57217 downregulated Bortezomib results in decreased expression of TTC7A mRNA 2p21 Bortezomib Approved Investigational TTL 150465 downregulated Bortezomib results in decreased expression of TTL mRNA 2q14.1 Bortezomib Approved Investigational TTPAL 79183 downregulated Bortezomib results in decreased expression of TTPAL mRNA 20q13.12 Bortezomib Approved Investigational TUBB2A 7280 upregulated Bortezomib results in increased expression of TUBB2A mRNA 6p25.2 Bortezomib Approved Investigational TUBD1 51174 upregulated Bortezomib results in increased expression of TUBD1 mRNA 17q23.1 Bortezomib Approved Investigational TXLNGY 246126 upregulated Bortezomib results in increased expression of TXLNGY mRNA Yq11.222-q11.223 Bortezomib Approved Investigational TXNDC9 10190 upregulated Bortezomib results in increased expression of TXNDC9 mRNA 2q11.2 Bortezomib Approved Investigational U2AF2 11338 downregulated Bortezomib results in decreased expression of U2AF2 mRNA 19q13.43 Bortezomib Approved Investigational UBR3 130507 upregulated Bortezomib results in increased expression of UBR3 mRNA 2q31.1 Bortezomib Approved Investigational UBXN4 23190 upregulated Bortezomib results in increased expression of UBXN4 mRNA 2q21.3 Bortezomib Approved Investigational UNC93B1 81622 downregulated Bortezomib results in decreased expression of UNC93B1 mRNA 11q13.2 Bortezomib Approved Investigational UNKL 64718 upregulated Bortezomib results in increased expression of UNKL mRNA 16p13.3 Bortezomib Approved Investigational UQCRB 7381 upregulated Bortezomib results in increased expression of UQCRB mRNA 8q22.1 Bortezomib Approved Investigational USP45 85015 upregulated Bortezomib results in increased expression of USP45 mRNA 6q16.2 Bortezomib Approved Investigational USP53 54532 upregulated Bortezomib results in increased expression of USP53 mRNA 4q26 Bortezomib Approved Investigational VASP 7408 downregulated Bortezomib results in decreased expression of VASP mRNA 19q13.32 Bortezomib Approved Investigational VCP 7415 upregulated Bortezomib results in increased expression of VCP mRNA 9p13.3 Bortezomib Approved Investigational VDAC1 7416 downregulated Bortezomib results in decreased expression of VDAC1 mRNA 5q31.1 Bortezomib Approved Investigational VEZT 55591 upregulated Bortezomib results in increased expression of VEZT mRNA 12q22 Bortezomib Approved Investigational WBP4 11193 upregulated Bortezomib results in increased expression of WBP4 mRNA 13q14.11 Bortezomib Approved Investigational WDR44 54521 upregulated Bortezomib results in increased expression of WDR44 mRNA Xq24 Bortezomib Approved Investigational WDR48 57599 upregulated Bortezomib results in increased expression of WDR48 mRNA 3p22.2 Bortezomib Approved Investigational WDR74 54663 upregulated Bortezomib results in increased expression of WDR74 mRNA 11q12.3 Bortezomib Approved Investigational WDR82 80335 upregulated Bortezomib results in increased expression of WDR82 mRNA 3p21.2 Bortezomib Approved Investigational WT1 7490 downregulated Bortezomib results in decreased expression of WT1 mRNA 11p13 Bortezomib Approved Investigational XAF1 54739 downregulated Bortezomib results in decreased expression of XAF1 mRNA 17p13.2 Bortezomib Approved Investigational XCL1 6375 downregulated Bortezomib results in decreased expression of XCL1 mRNA 1q24.2 Bortezomib Approved Investigational XIAP 331 upregulated Bortezomib results in increased expression of XIAP mRNA Xq25 Bortezomib Approved Investigational XPNPEP3 63929 downregulated Bortezomib results in decreased expression of XPNPEP3 mRNA 22q13.2 Bortezomib Approved Investigational XPO5 57510 downregulated Bortezomib results in decreased expression of XPO5 mRNA 6p21.1 Bortezomib Approved Investigational XRCC3 7517 downregulated Bortezomib results in decreased expression of XRCC3 mRNA 14q32.3 Bortezomib Approved Investigational XXYLT1 152002 downregulated Bortezomib results in decreased expression of XXYLT1 mRNA 3q29 Bortezomib Approved Investigational YES1 7525 upregulated Bortezomib results in increased expression of YES1 mRNA 18p11.32 Bortezomib Approved Investigational YPEL5 51646 upregulated Bortezomib results in increased expression of YPEL5 mRNA 2p23.1 Bortezomib Approved Investigational YWHAE 7531 downregulated Bortezomib results in decreased expression of YWHAE mRNA 17p13.3 Bortezomib Approved Investigational YWHAZ 7534 upregulated Bortezomib results in increased expression of YWHAZ mRNA 8q22.3 Bortezomib Approved Investigational ZBTB3 79842 upregulated Bortezomib results in increased expression of ZBTB3 mRNA 11q12.3 Bortezomib Approved Investigational ZCCHC2 54877 upregulated Bortezomib results in increased expression of ZCCHC2 mRNA 18q21.33 Bortezomib Approved Investigational ZFAND2A 90637 upregulated Bortezomib results in increased expression of ZFAND2A mRNA 7p22.3 Bortezomib Approved Investigational ZFPM1 161882 downregulated Bortezomib results in decreased expression of ZFPM1 mRNA 16q24.2 Bortezomib Approved Investigational ZFX 7543 upregulated Bortezomib results in increased expression of ZFX mRNA Xp22.11 Bortezomib Approved Investigational ZGPAT 84619 upregulated Bortezomib results in increased expression of ZGPAT mRNA 20q13.33 Bortezomib Approved Investigational ZMYND11 10771 downregulated Bortezomib results in decreased expression of ZMYND11 mRNA 10p15.3 Bortezomib Approved Investigational ZMYND8 23613 downregulated Bortezomib results in decreased expression of ZMYND8 mRNA 20q13.12 Bortezomib Approved Investigational ZNF165 7718 upregulated Bortezomib results in increased expression of ZNF165 mRNA 6p22.1 Bortezomib Approved Investigational ZNF23 7571 upregulated Bortezomib results in increased expression of ZNF23 mRNA 16q22.2 Bortezomib Approved Investigational ZNF335 63925 downregulated Bortezomib results in decreased expression of ZNF335 mRNA 20q13.12 Bortezomib Approved Investigational ZNF580 51157 downregulated Bortezomib results in decreased expression of ZNF580 mRNA 19q13.42 Bortezomib Approved Investigational ZNF768 79724 downregulated Bortezomib results in decreased expression of ZNF768 mRNA 16p11.2 Bortezomib Approved Investigational ZNF787 126208 upregulated Bortezomib results in increased expression of ZNF787 mRNA 19q13.43 Bortezomib Approved Investigational ZNF92 168374 upregulated Bortezomib results in increased expression of ZNF92 mRNA 7q11.21 Bortezomib Approved Investigational ZNRF2 223082 upregulated Bortezomib results in increased expression of ZNRF2 mRNA 7p14.3 Zoledronic acid Approved ABCA4 24 upregulated zoledronic acid results in increased expression of ABCA4 mRNA 1p22.1 Zoledronic acid Approved ACBD4 79777 downregulated zoledronic acid results in decreased expression of ACBD4 mRNA 17q21.31 Zoledronic acid Approved ADGRL1 22859 downregulated zoledronic acid results in decreased expression of ADGRL1 mRNA 19p13.12 Zoledronic acid Approved ADSL 158 downregulated zoledronic acid results in decreased expression of ADSL mRNA 22q13.1 Zoledronic acid Approved AKIRIN2 55122 downregulated zoledronic acid results in decreased expression of AKIRIN2 mRNA 6q15 Zoledronic acid Approved AKT1S1 84335 upregulated zoledronic acid results in increased expression of AKT1S1 mRNA 19q13.33 Zoledronic acid Approved ALOX5AP 241 upregulated zoledronic acid results in increased expression of ALOX5AP mRNA 13q12.3 Zoledronic acid Approved ANKEF1 63926 upregulated zoledronic acid results in increased expression of ANKEF1 mRNA 20p12.2 Zoledronic acid Approved ANKRD10 55608 upregulated zoledronic acid results in increased expression of ANKRD10 mRNA 13q34 Zoledronic acid Approved AP1S3 130340 upregulated zoledronic acid results in increased expression of AP1S3 mRNA 2q36.1 Zoledronic acid Approved APBA3 9546 downregulated zoledronic acid results in decreased expression of APBA3 mRNA 19p13.3 Zoledronic acid Approved APH1A 51107 upregulated zoledronic acid results in increased expression of APH1A mRNA 1q21.2 Zoledronic acid Approved API5 8539 upregulated zoledronic acid results in increased expression of API5 mRNA 11p12 Zoledronic acid Approved ARAP1 116985 downregulated zoledronic acid results in decreased expression of ARAP1 mRNA 11q13.4 Zoledronic acid Approved ARHGAP18 93663 downregulated zoledronic acid results in decreased expression of ARHGAP18 mRNA 6q22.33 Zoledronic acid Approved ARHGAP19 84986 downregulated zoledronic acid results in decreased expression of ARHGAP19 mRNA 10q24.1 Zoledronic acid Approved ARID2 196528 downregulated zoledronic acid results in decreased expression of ARID2 mRNA 12q12 Zoledronic acid Approved ARL5B 221079 upregulated zoledronic acid results in increased expression of ARL5B mRNA 10p12.31 Zoledronic acid Approved ARNTL 406 upregulated zoledronic acid results in increased expression of ARNTL mRNA 11p15.3 Zoledronic acid Approved ATRX 546 downregulated zoledronic acid results in decreased expression of ATRX mRNA Xq21.1 Zoledronic acid Approved BBX 56987 downregulated zoledronic acid results in decreased expression of BBX mRNA 3q13.12 Zoledronic acid Approved BICDL1 92558 upregulated zoledronic acid results in increased expression of BICDL1 mRNA 12q24.23 Zoledronic acid Approved BLOC1S5 63915 upregulated zoledronic acid results in increased expression of BLOC1S5 mRNA 6p24.3 Zoledronic acid Approved BMP1 649 upregulated zoledronic acid results in increased expression of BMP1 mRNA 8p21.3 Zoledronic acid Approved BMPR2 659 upregulated zoledronic acid results in increased expression of BMPR2 mRNA 2q33.1-q33.2 Zoledronic acid Approved BRCA2 675 upregulated zoledronic acid results in increased expression of BRCA2 mRNA 13q13.1 Zoledronic acid Approved BRIP1 83990 upregulated zoledronic acid results in increased expression of BRIP1 mRNA 17q23.2 Zoledronic acid Approved BTG2 7832 upregulated zoledronic acid results in increased expression of BTG2 mRNA 1q32.1 Zoledronic acid Approved CALML4 91860 downregulated zoledronic acid results in decreased expression of CALML4 mRNA 15q23 Zoledronic acid Approved CANT1 124583 upregulated zoledronic acid results in increased expression of CANT1 mRNA 17q25.3 Zoledronic acid Approved CAPRIN1 4076 upregulated zoledronic acid results in increased expression of CAPRIN1 mRNA 11p13 Zoledronic acid Approved CARD8 22900 upregulated zoledronic acid results in increased expression of CARD8 mRNA 19q13.33 Zoledronic acid Approved CARS 833 upregulated zoledronic acid results in increased expression of CARS mRNA 11p15.4 Zoledronic acid Approved CASP8 841 upregulated zoledronic acid results in increased expression of CASP8 mRNA 2q33.1 Zoledronic acid Approved CBX5 23468 upregulated zoledronic acid results in increased expression of CBX5 mRNA 12q13.13 Zoledronic acid Approved CCDC138 165055 upregulated zoledronic acid results in increased expression of CCDC138 mRNA 2q13 Zoledronic acid Approved CCL20 6364 upregulated zoledronic acid results in increased expression of CCL20 mRNA 2q36.3 Zoledronic acid Approved CCNB1 891 downregulated zoledronic acid results in decreased expression of CCNB1 mRNA 5q13.2 Zoledronic acid Approved CCNE2 9134 upregulated zoledronic acid results in increased expression of CCNE2 mRNA 8q22.1 Zoledronic acid Approved CCT6P1 643253 upregulated zoledronic acid results in increased expression of CCT6P1 mRNA 7q11.21 Zoledronic acid Approved CD55 1604 upregulated zoledronic acid results in increased expression of CD55 mRNA 1q32.2 Zoledronic acid Approved CDC20 991 downregulated zoledronic acid results in decreased expression of CDC20 mRNA 1p34.2 Zoledronic acid Approved CDC25C 995 upregulated zoledronic acid results in increased expression of CDC25C mRNA 5q31.2 Zoledronic acid Approved CDKN1C 1028 upregulated zoledronic acid results in increased expression of CDKN1C mRNA 11p15.4 Zoledronic acid Approved CDV3 55573 upregulated zoledronic acid results in increased expression of CDV3 mRNA 3q22.1 Zoledronic acid Approved CEBPA 1050 upregulated zoledronic acid results in increased expression of CEBPA mRNA 19q13.11 Zoledronic acid Approved CENPI 2491 upregulated zoledronic acid results in increased expression of CENPI mRNA Xq22.1 Zoledronic acid Approved CEP120 153241 upregulated zoledronic acid results in increased expression of CEP120 mRNA 5q23.2 Zoledronic acid Approved CEP295 85459 upregulated zoledronic acid results in increased expression of CEP295 mRNA 11q21 Zoledronic acid Approved CEP57 9702 upregulated zoledronic acid results in increased expression of CEP57 mRNA 11q21 Zoledronic acid Approved CHAC1 79094 upregulated zoledronic acid results in increased expression of CHAC1 mRNA 15q15.1 Zoledronic acid Approved CHMP4B 128866 upregulated zoledronic acid results in increased expression of CHMP4B mRNA 20q11.22 Zoledronic acid Approved CLDN3 1365 upregulated zoledronic acid results in increased expression of CLDN3 mRNA 7q11.23 Zoledronic acid Approved COQ4 51117 downregulated zoledronic acid results in decreased expression of COQ4 mRNA 9q34.11 Zoledronic acid Approved COX17 10063 downregulated zoledronic acid results in decreased expression of COX17 mRNA 3q13.33 Zoledronic acid Approved CPD 1362 upregulated zoledronic acid results in increased expression of CPD mRNA 17q11.2 Zoledronic acid Approved CPNE3 8895 upregulated zoledronic acid results in increased expression of CPNE3 mRNA 8q21.3 Zoledronic acid Approved CRLS1 54675 downregulated zoledronic acid results in decreased expression of CRLS1 mRNA 20p12.3 Zoledronic acid Approved CSF1 1435 downregulated zoledronic acid results in decreased expression of CSF1 mRNA 1p13.3 Zoledronic acid Approved CTBS 1486 upregulated zoledronic acid results in increased expression of CTBS mRNA 1p22.3 Zoledronic acid Approved CTU2 348180 downregulated zoledronic acid results in decreased expression of CTU2 mRNA 16q24.3 Zoledronic acid Approved CYB5R3 1727 upregulated zoledronic acid results in increased expression of CYB5R3 mRNA 22q13.2 Zoledronic acid Approved DAPP1 27071 upregulated zoledronic acid results in increased expression of DAPP1 mRNA 4q23 Zoledronic acid Approved DCAF15 90379 upregulated zoledronic acid results in increased expression of DCAF15 mRNA 19p13.12 Zoledronic acid Approved DCUN1D4 23142 upregulated zoledronic acid results in increased expression of DCUN1D4 mRNA 4q12 Zoledronic acid Approved DDX42 11325 upregulated zoledronic acid results in increased expression of DDX42 mRNA 17q23.3 Zoledronic acid Approved DFFA 1676 downregulated zoledronic acid results in decreased expression of DFFA mRNA 1p36.22 Zoledronic acid Approved DHX35 60625 upregulated zoledronic acid results in increased expression of DHX35 mRNA 20q11.23-q12 Zoledronic acid Approved DLG1 1739 upregulated zoledronic acid results in increased expression of DLG1 mRNA 3q29 Zoledronic acid Approved DLGAP4 22839 downregulated zoledronic acid results in decreased expression of DLGAP4 mRNA 20q11.23 Zoledronic acid Approved DNAJB9 4189 upregulated zoledronic acid results in increased expression of DNAJB9 mRNA 7q31.1 Zoledronic acid Approved DNASE1L1 1774 upregulated zoledronic acid results in increased expression of DNASE1L1 mRNA Xq28 Zoledronic acid Approved DPP9 91039 upregulated zoledronic acid results in increased expression of DPP9 mRNA 19p13.3 Zoledronic acid Approved DTWD2 285605 downregulated zoledronic acid results in decreased expression of DTWD2 mRNA 5q23.1 Zoledronic acid Approved DTX3 196403 upregulated zoledronic acid results in increased expression of DTX3 mRNA 12q13.3 Zoledronic acid Approved DUSP18 150290 upregulated zoledronic acid results in increased expression of DUSP18 mRNA 22q12.2 Zoledronic acid Approved E2F2 1870 upregulated zoledronic acid results in increased expression of E2F2 mRNA 1p36.12 Zoledronic acid Approved EGLN2 112398 upregulated zoledronic acid results in increased expression of EGLN2 mRNA 19q13.2 Zoledronic acid Approved EGR1 1958 upregulated zoledronic acid results in increased expression of EGR1 mRNA 5q31.2 Zoledronic acid Approved EGR2 1959 upregulated zoledronic acid results in increased expression of EGR2 mRNA 10q21.3 Zoledronic acid Approved EGR4 1961 upregulated zoledronic acid results in increased expression of EGR4 mRNA 2p13.2 Zoledronic acid Approved ELK1 2002 upregulated zoledronic acid results in increased expression of ELK1 mRNA Xp11.23 Zoledronic acid Approved ELL2 22936 upregulated zoledronic acid results in increased expression of ELL2 mRNA 5q15 Zoledronic acid Approved EML4 27436 upregulated zoledronic acid results in increased expression of EML4 mRNA 2p21 Zoledronic acid Approved EMP3 2014 upregulated zoledronic acid results in increased expression of EMP3 mRNA 19q13.33 Zoledronic acid Approved ERGIC2 51290 downregulated zoledronic acid results in decreased expression of ERGIC2 mRNA 12p11.22 Zoledronic acid Approved ERLIN1 10613 upregulated zoledronic acid results in increased expression of ERLIN1 mRNA 10q24.31 Zoledronic acid Approved ESCO2 157570 upregulated zoledronic acid results in increased expression of ESCO2 mRNA 8p21.1 Zoledronic acid Approved EXOC5 10640 upregulated zoledronic acid results in increased expression of EXOC5 mRNA 14q22.3 Zoledronic acid Approved EZR 7430 upregulated zoledronic acid results in increased expression of EZR mRNA 6q25.3 Zoledronic acid Approved FADS3 3995 upregulated zoledronic acid results in increased expression of FADS3 mRNA 11q12.2 Zoledronic acid Approved FAM222B 55731 downregulated zoledronic acid results in decreased expression of FAM222B mRNA 17q11.2 Zoledronic acid Approved FAM57A 79850 upregulated zoledronic acid results in increased expression of FAM57A mRNA 17p13.3 Zoledronic acid Approved FBN1 2200 upregulated zoledronic acid results in increased expression of FBN1 mRNA 15q21.1 Zoledronic acid Approved FEM1B 10116 upregulated zoledronic acid results in increased expression of FEM1B mRNA 15q23 Zoledronic acid Approved FHL1 2273 upregulated zoledronic acid results in increased expression of FHL1 mRNA Xq26.3 Zoledronic acid Approved FIGNL1 63979 upregulated zoledronic acid results in increased expression of FIGNL1 mRNA 7p12.2 Zoledronic acid Approved FOPNL 123811 upregulated zoledronic acid results in increased expression of FOPNL mRNA 16p13.11 Zoledronic acid Approved FSCN1 6624 upregulated zoledronic acid results in increased expression of FSCN1 mRNA 7p22.1 Zoledronic acid Approved GADD45B 4616 upregulated zoledronic acid results in increased expression of GADD45B mRNA 19p13.3 Zoledronic acid Approved GK 2710 upregulated zoledronic acid results in increased expression of GK mRNA Xp21.2 Zoledronic acid Approved GLG1 2734 downregulated zoledronic acid results in decreased expression of GLG1 mRNA 16q23.1 Zoledronic acid Approved GLIPR1 11010 downregulated zoledronic acid results in decreased expression of GLIPR1 mRNA 12q21.2 Zoledronic acid Approved GLRX3 10539 downregulated zoledronic acid results in decreased expression of GLRX3 mRNA 10q26.3 Zoledronic acid Approved GNB4 59345 upregulated zoledronic acid results in increased expression of GNB4 mRNA 3q26.33 Zoledronic acid Approved GTF2I 2969 upregulated zoledronic acid results in increased expression of GTF2I mRNA 7q11.23 Zoledronic acid Approved GTF3C4 9329 upregulated zoledronic acid results in increased expression of GTF3C4 mRNA 9q34.13 Zoledronic acid Approved GTPBP2 54676 upregulated zoledronic acid results in increased expression of GTPBP2 mRNA 6p21.1 Zoledronic acid Approved H2AFX 3014 upregulated zoledronic acid results in increased expression of H2AFX mRNA 11q23.3 Zoledronic acid Approved HERC4 26091 downregulated zoledronic acid results in decreased expression of HERC4 mRNA 10q21.3 Zoledronic acid Approved HIST1H4C 8364 downregulated zoledronic acid results in decreased expression of HIST1H4C mRNA 6p22.2 Zoledronic acid Approved HP1BP3 50809 upregulated zoledronic acid results in increased expression of HP1BP3 mRNA 1p36.12 Zoledronic acid Approved HS3ST3B1 9953 downregulated zoledronic acid results in decreased expression of HS3ST3B1 mRNA 17p12 Zoledronic acid Approved HTR4 3360 upregulated zoledronic acid results in increased expression of HTR4 mRNA 5q32 Zoledronic acid Approved IFT81 28981 downregulated zoledronic acid results in decreased expression of IFT81 mRNA 12q24.11 Zoledronic acid Approved IKZF5 64376 downregulated zoledronic acid results in decreased expression of IKZF5 mRNA 10q26.13 Zoledronic acid Approved IL23A 51561 upregulated zoledronic acid results in increased expression of IL23A mRNA 12q13.3 Zoledronic acid Approved INHBE 83729 upregulated zoledronic acid results in increased expression of INHBE mRNA 12q13.3 Zoledronic acid Approved IREB2 3658 upregulated zoledronic acid results in increased expression of IREB2 mRNA 15q25.1 Zoledronic acid Approved IRF2BP1 26145 downregulated zoledronic acid results in decreased expression of IRF2BP1 mRNA 19q13.32 Zoledronic acid Approved JAK3 3718 upregulated zoledronic acid results in increased expression of JAK3 mRNA 19p13.11 Zoledronic acid Approved JOSD1 9929 upregulated zoledronic acid results in increased expression of JOSD1 mRNA 22q13.1 Zoledronic acid Approved KBTBD2 25948 upregulated zoledronic acid results in increased expression of KBTBD2 mRNA 7p14.3 Zoledronic acid Approved KCTD5 54442 upregulated zoledronic acid results in increased expression of KCTD5 mRNA 16p13.3 Zoledronic acid Approved KIF20A 10112 downregulated zoledronic acid results in decreased expression of KIF20A mRNA 5q31.2 Zoledronic acid Approved KIR2DL1 3802 upregulated zoledronic acid results in increased expression of KIR2DL1 mRNA 19q13.42 Zoledronic acid Approved KLF11 8462 upregulated zoledronic acid results in increased expression of KLF11 mRNA 2p25.1 Zoledronic acid Approved KLF7 8609 upregulated zoledronic acid results in increased expression of KLF7 mRNA 2q33.3 Zoledronic acid Approved KLHL23 151230 upregulated zoledronic acid results in increased expression of KLHL23 mRNA 2q31.1 Zoledronic acid Approved KRCC1 51315 upregulated zoledronic acid results in increased expression of KRCC1 mRNA 2p11.2 Zoledronic acid Approved LAMA3 3909 upregulated zoledronic acid results in increased expression of LAMA3 mRNA 18q11.2 Zoledronic acid Approved LDLR 3949 upregulated zoledronic acid results in increased expression of LDLR mRNA 19p13.2 Zoledronic acid Approved LHX3 8022 upregulated zoledronic acid results in increased expression of LHX3 mRNA 9q34.3 Zoledronic acid Approved LIN52 91750 upregulated zoledronic acid results in increased expression of LIN52 mRNA 14q24.3 Zoledronic acid Approved LINS1 55180 upregulated zoledronic acid results in increased expression of LINS1 mRNA 15q26.3 Zoledronic acid Approved LNPEP 4012 upregulated zoledronic acid results in increased expression of LNPEP mRNA 5q15 Zoledronic acid Approved LPIN1 23175 upregulated zoledronic acid results in increased expression of LPIN1 mRNA 2p25.1 Zoledronic acid Approved LRRC14 9684 upregulated zoledronic acid results in increased expression of LRRC14 mRNA 8q24.3 Zoledronic acid Approved MAP3K2 10746 downregulated zoledronic acid results in decreased expression of MAP3K2 mRNA 2q14.3 Zoledronic acid Approved MAP7D3 79649 upregulated zoledronic acid results in increased expression of MAP7D3 mRNA Xq26.3 Zoledronic acid Approved MAX 4149 upregulated zoledronic acid results in increased expression of MAX mRNA 14q23.3 Zoledronic acid Approved MBTPS2 51360 upregulated zoledronic acid results in increased expression of MBTPS2 mRNA Xp22.12 Zoledronic acid Approved MCM4 4173 upregulated zoledronic acid results in increased expression of MCM4 mRNA 8q11.21 Zoledronic acid Approved MDM4 4194 upregulated zoledronic acid results in increased expression of MDM4 mRNA 1q32.1 Zoledronic acid Approved MED13L 23389 downregulated zoledronic acid results in decreased expression of MED13L mRNA 12q24.21 Zoledronic acid Approved MED20 9477 upregulated zoledronic acid results in increased expression of MED20 mRNA 6p21.1 Zoledronic acid Approved MEX3C 51320 upregulated zoledronic acid results in increased expression of MEX3C mRNA 18q21.2 Zoledronic acid Approved MINK1 50488 downregulated zoledronic acid results in decreased expression of MINK1 mRNA 17p13.2 Zoledronic acid Approved MMEL1 79258 upregulated zoledronic acid results in increased expression of MMEL1 mRNA 1p36.32 Zoledronic acid Approved MPDU1 9526 upregulated zoledronic acid results in increased expression of MPDU1 mRNA 17p13.1 Zoledronic acid Approved MREG 55686 upregulated zoledronic acid results in increased expression of MREG mRNA 2q35 Zoledronic acid Approved MSH3 4437 upregulated zoledronic acid results in increased expression of MSH3 mRNA 5q14.1 Zoledronic acid Approved MTERF4 130916 upregulated zoledronic acid results in increased expression of MTERF4 mRNA 2q37.3 Zoledronic acid Approved MTPAP 55149 upregulated zoledronic acid results in increased expression of MTPAP mRNA 10p11.23 Zoledronic acid Approved MVK 4598 upregulated zoledronic acid results in increased expression of MVK mRNA 12q24.11 Zoledronic acid Approved MVP 9961 downregulated zoledronic acid results in decreased expression of MVP mRNA 16p11.2 Zoledronic acid Approved N4BP2L1 90634 upregulated zoledronic acid results in increased expression of N4BP2L1 mRNA 13q13.1 Zoledronic acid Approved NACAP1 83955 downregulated zoledronic acid results in decreased expression of NACAP1 mRNA 8q22.3 Zoledronic acid Approved NANOS1 340719 upregulated zoledronic acid results in increased expression of NANOS1 mRNA 10q26.11 Zoledronic acid Approved NBR1 4077 upregulated zoledronic acid results in increased expression of NBR1 mRNA 17q21.31 Zoledronic acid Approved NDE1 54820 upregulated zoledronic acid results in increased expression of NDE1 mRNA 16p13.11 Zoledronic acid Approved NEMP1 23306 upregulated zoledronic acid results in increased expression of NEMP1 mRNA 12q13.3 Zoledronic acid Approved NFE2L2 4780 upregulated zoledronic acid results in increased expression of NFE2L2 mRNA 2q31.2 Zoledronic acid Approved NFE2L3 9603 downregulated zoledronic acid results in decreased expression of NFE2L3 mRNA 7p15.2 Zoledronic acid Approved NKRF 55922 downregulated zoledronic acid results in decreased expression of NKRF mRNA Xq24 Zoledronic acid Approved NPAT 4863 upregulated zoledronic acid results in increased expression of NPAT mRNA 11q22.3 Zoledronic acid Approved NREP 9315 upregulated zoledronic acid results in increased expression of NREP mRNA 5q22.1 Zoledronic acid Approved NXT2 55916 upregulated zoledronic acid results in increased expression of NXT2 mRNA Xq23 Zoledronic acid Approved OR51B2 79345 upregulated zoledronic acid results in increased expression of OR51B2 mRNA 11p15.4 Zoledronic acid Approved OSGEPL1 64172 downregulated zoledronic acid results in decreased expression of OSGEPL1 mRNA 2q32.2 Zoledronic acid Approved P4HB 5034 upregulated zoledronic acid results in increased expression of P4HB mRNA 17q25.3 Zoledronic acid Approved PCGF5 84333 upregulated zoledronic acid results in increased expression of PCGF5 mRNA 10q23.32 Zoledronic acid Approved PCYOX1 51449 upregulated zoledronic acid results in increased expression of PCYOX1 mRNA 2p13.3 Zoledronic acid Approved PDLIM7 9260 upregulated zoledronic acid results in increased expression of PDLIM7 mRNA 5q35.3 Zoledronic acid Approved PGLYRP4 57115 upregulated zoledronic acid results in increased expression of PGLYRP4 mRNA 1q21.3 Zoledronic acid Approved PHPT1 29085 upregulated zoledronic acid results in increased expression of PHPT1 mRNA 9q34.3 Zoledronic acid Approved PIK3C2A 5286 upregulated zoledronic acid results in increased expression of PIK3C2A mRNA 11p15.1 Zoledronic acid Approved PILRB 29990 upregulated zoledronic acid results in increased expression of PILRB mRNA 7q22.1 Zoledronic acid Approved PLAU 5328 upregulated zoledronic acid results in increased expression of PLAU mRNA 10q22.2 Zoledronic acid Approved PLEK 5341 upregulated zoledronic acid results in increased expression of PLEK mRNA 2p14 Zoledronic acid Approved PLK1 5347 downregulated zoledronic acid results in decreased expression of PLK1 mRNA 16p12.2 Zoledronic acid Approved PMS2P2 5380 upregulated zoledronic acid results in increased expression of PMS2P2 mRNA 7q11.23 Zoledronic acid Approved PNRC2 55629 upregulated zoledronic acid results in increased expression of PNRC2 mRNA 1p36.11 Zoledronic acid Approved POLR2A 5430 downregulated zoledronic acid results in decreased expression of POLR2A mRNA 17p13.1 Zoledronic acid Approved POLR2D 5433 upregulated zoledronic acid results in increased expression of POLR2D mRNA 2q14.3 Zoledronic acid Approved POMGNT1 55624 upregulated zoledronic acid results in increased expression of POMGNT1 mRNA 1p34.1 Zoledronic acid Approved PPP1R15A 23645 upregulated zoledronic acid results in increased expression of PPP1R15A mRNA 19q13.2 Zoledronic acid Approved PRKACB 5567 upregulated zoledronic acid results in increased expression of PRKACB mRNA 1p31.1 Zoledronic acid Approved PROSER3 148137 upregulated zoledronic acid results in increased expression of PROSER3 mRNA 19q13.12 Zoledronic acid Approved PRR14 78994 upregulated zoledronic acid results in increased expression of PRR14 mRNA 16p11.2 Zoledronic acid Approved PRRG4 79056 upregulated zoledronic acid results in increased expression of PRRG4 mRNA 11p13 Zoledronic acid Approved PRSS3 5646 upregulated zoledronic acid results in increased expression of PRSS3 mRNA 9p13.3 Zoledronic acid Approved PSRC1 84722 downregulated zoledronic acid results in decreased expression of PSRC1 mRNA 1p13.3 Zoledronic acid Approved PTGS2 5743 downregulated zoledronic acid results in decreased expression of PTGS2 mRNA 1q31.1 Zoledronic acid Approved PTK2 5747 upregulated zoledronic acid results in increased expression of PTK2 mRNA 8q24.3 Zoledronic acid Approved RAB23 51715 upregulated zoledronic acid results in increased expression of RAB23 mRNA 6p12.1-p11.2 Zoledronic acid Approved RAB6A 5870 upregulated zoledronic acid results in increased expression of RAB6A mRNA 11q13.4 Zoledronic acid Approved RAD51D 5892 upregulated zoledronic acid results in increased expression of RAD51D mRNA 17q12 Zoledronic acid Approved RASSF5 83593 upregulated zoledronic acid results in increased expression of RASSF5 mRNA 1q32.1 Zoledronic acid Approved RBBP9 10741 upregulated zoledronic acid results in increased expression of RBBP9 mRNA 20p11.23 Zoledronic acid Approved RBM14 10432 upregulated zoledronic acid results in increased expression of RBM14 mRNA 11q13.2 Zoledronic acid Approved RBM8A 9939 upregulated zoledronic acid results in increased expression of RBM8A mRNA 1q21.1 Zoledronic acid Approved RGS14 10636 upregulated zoledronic acid results in increased expression of RGS14 mRNA 5q35.3 Zoledronic acid Approved RHBDD2 57414 upregulated zoledronic acid results in increased expression of RHBDD2 mRNA 7q11.23 Zoledronic acid Approved RHOB 388 upregulated zoledronic acid results in increased expression of RHOB mRNA 2p24.1 Zoledronic acid Approved RNF114 55905 upregulated zoledronic acid results in increased expression of RNF114 mRNA 20q13.13 Zoledronic acid Approved RNF141 50862 downregulated zoledronic acid results in decreased expression of RNF141 mRNA 11p15.3 Zoledronic acid Approved RNF167 26001 upregulated zoledronic acid results in increased expression of RNF167 mRNA 17p13.2 Zoledronic acid Approved RPL7 6129 upregulated zoledronic acid results in increased expression of RPL7 mRNA 8q21.11 Zoledronic acid Approved RPS9 6203 downregulated zoledronic acid results in decreased expression of RPS9 mRNA 19q13.42 Zoledronic acid Approved RPTOR 57521 downregulated zoledronic acid results in decreased expression of RPTOR mRNA 17q25.3 Zoledronic acid Approved RSRC1 51319 downregulated zoledronic acid results in decreased expression of RSRC1 mRNA 3q25.32 Zoledronic acid Approved SCOC 60592 upregulated zoledronic acid results in increased expression of SCOC mRNA 4q31.1 Zoledronic acid Approved SECISBP2L 9728 upregulated zoledronic acid results in increased expression of SECISBP2L mRNA 15q21.1 Zoledronic acid Approved SERPINH1 871 upregulated zoledronic acid results in increased expression of SERPINH1 mRNA 11q13.5 Zoledronic acid Approved SETD1A 9739 downregulated zoledronic acid results in decreased expression of SETD1A mRNA 16p11.2 Zoledronic acid Approved SFXN3 81855 downregulated zoledronic acid results in decreased expression of SFXN3 mRNA 10q24.31 Zoledronic acid Approved SHROOM1 134549 upregulated zoledronic acid results in increased expression of SHROOM1 mRNA 5q31.1 Zoledronic acid Approved SLC16A1 6566 upregulated zoledronic acid results in increased expression of SLC16A1 mRNA 1p13.2 Zoledronic acid Approved SLC23A2 9962 upregulated zoledronic acid results in increased expression of SLC23A2 mRNA 20p13 Zoledronic acid Approved SLC25A40 55972 upregulated zoledronic acid results in increased expression of SLC25A40 mRNA 7q21.12 Zoledronic acid Approved SLC27A1 376497 upregulated zoledronic acid results in increased expression of SLC27A1 mRNA 19p13.11 Zoledronic acid Approved SLCO3A1 28232 downregulated zoledronic acid results in decreased expression of SLCO3A1 mRNA 15q26.1 Zoledronic acid Approved SLMAP 7871 upregulated zoledronic acid results in increased expression of SLMAP mRNA 3p14.3 Zoledronic acid Approved SNHG12 85028 upregulated zoledronic acid results in increased expression of SNHG12 mRNA 1p35.3 Zoledronic acid Approved SOX13 9580 upregulated zoledronic acid results in increased expression of SOX13 mRNA 1q32.1 Zoledronic acid Approved SP1 6667 upregulated zoledronic acid results in increased expression of SP1 mRNA 12q13.13 Zoledronic acid Approved SPATA7 55812 upregulated zoledronic acid results in increased expression of SPATA7 mRNA 14q31.3 Zoledronic acid Approved SPRYD3 84926 downregulated zoledronic acid results in decreased expression of SPRYD3 mRNA 12q13.13 Zoledronic acid Approved SQLE 6713 upregulated zoledronic acid results in increased expression of SQLE mRNA 8q24.13 Zoledronic acid Approved SRSF11 9295 downregulated zoledronic acid results in decreased expression of SRSF11 mRNA 1p31.1 Zoledronic acid Approved SS18 6760 upregulated zoledronic acid results in increased expression of SS18 mRNA 18q11.2 Zoledronic acid Approved SSX2IP 117178 upregulated zoledronic acid results in increased expression of SSX2IP mRNA 1p22.3 Zoledronic acid Approved ST6GAL1 6480 upregulated zoledronic acid results in increased expression of ST6GAL1 mRNA 3q27.3 Zoledronic acid Approved STK40 83931 downregulated zoledronic acid results in decreased expression of STK40 mRNA 1p34.3 Zoledronic acid Approved STX16 8675 upregulated zoledronic acid results in increased expression of STX16 mRNA 20q13.32 Zoledronic acid Approved STX17 55014 upregulated zoledronic acid results in increased expression of STX17 mRNA 9q31.1 Zoledronic acid Approved SYNJ1 8867 upregulated zoledronic acid results in increased expression of SYNJ1 mRNA 21q22.11 Zoledronic acid Approved TAB2 23118 upregulated zoledronic acid results in increased expression of TAB2 mRNA 6q25.1 Zoledronic acid Approved TAF9B 51616 upregulated zoledronic acid results in increased expression of TAF9B mRNA Xq21.1 Zoledronic acid Approved TBL1XR1 79718 upregulated zoledronic acid results in increased expression of TBL1XR1 mRNA 3q26.32 Zoledronic acid Approved TCAIM 285343 upregulated zoledronic acid results in increased expression of TCAIM mRNA 3p21.31 Zoledronic acid Approved TESPA1 9840 downregulated zoledronic acid results in decreased expression of TESPA1 mRNA 12q13.2 Zoledronic acid Approved TFIP11 24144 downregulated zoledronic acid results in decreased expression of TFIP11 mRNA 22q12.1 Zoledronic acid Approved TFRC 7037 upregulated zoledronic acid results in increased expression of TFRC mRNA 3q29 Zoledronic acid Approved TMCO3 55002 upregulated zoledronic acid results in increased expression of TMCO3 mRNA 13q34 Zoledronic acid Approved TMEM259 91304 upregulated zoledronic acid results in increased expression of TMEM259 mRNA 19p13.3 Zoledronic acid Approved TMEM30A 55754 upregulated zoledronic acid results in increased expression of TMEM30A mRNA 6q14.1 Zoledronic acid Approved TMEM87B 84910 upregulated zoledronic acid results in increased expression of TMEM87B mRNA 2q13 Zoledronic acid Approved TMEM99 147184 upregulated zoledronic acid results in increased expression of TMEM99 mRNA 17q21.2 Zoledronic acid Approved TMTC2 160335 upregulated zoledronic acid results in increased expression of TMTC2 mRNA 12q21.31 Zoledronic acid Approved TNFAIP6 7130 upregulated zoledronic acid results in increased expression of TNFAIP6 mRNA 2q23.3 Zoledronic acid Approved TNFSF8 944 upregulated zoledronic acid results in increased expression of TNFSF8 mRNA 9q32-q33.1 Zoledronic acid Approved TNPO3 23534 downregulated zoledronic acid results in decreased expression of TNPO3 mRNA 7q32.1 Zoledronic acid Approved TOB1 10140 upregulated zoledronic acid results in increased expression of TOB1 mRNA 17q21.33 Zoledronic acid Approved TOLLIP 54472 upregulated zoledronic acid results in increased expression of TOLLIP mRNA 11p15.5 Zoledronic acid Approved TOX4 9878 upregulated zoledronic acid results in increased expression of TOX4 mRNA 14q11.2 Zoledronic acid Approved TRAIP 10293 upregulated zoledronic acid results in increased expression of TRAIP mRNA 3p21.31 Zoledronic acid Approved TRIB3 57761 upregulated zoledronic acid results in increased expression of TRIB3 mRNA 20p13 Zoledronic acid Approved TRIM22 10346 upregulated zoledronic acid results in increased expression of TRIM22 mRNA 11p15.4 Zoledronic acid Approved TRIQK 286144 upregulated zoledronic acid results in increased expression of TRIQK mRNA 8q22.1 Zoledronic acid Approved TSC22D3 1831 upregulated zoledronic acid results in increased expression of TSC22D3 mRNA Xq22.3 Zoledronic acid Approved TXNIP 10628 upregulated zoledronic acid results in increased expression of TXNIP mRNA 1q21.1 Zoledronic acid Approved ULK2 9706 upregulated zoledronic acid results in increased expression of ULK2 mRNA 17p11.2 Zoledronic acid Approved UNC13D 201294 upregulated zoledronic acid results in increased expression of UNC13D mRNA 17q25.3 Zoledronic acid Approved USP24 23358 downregulated zoledronic acid results in decreased expression of USP24 mRNA 1p32.3 Zoledronic acid Approved USP31 57478 upregulated zoledronic acid results in increased expression of USP31 mRNA 16p12.2 Zoledronic acid Approved VAMP3 9341 upregulated zoledronic acid results in increased expression of VAMP3 mRNA 1p36.23 Zoledronic acid Approved VANGL1 81839 downregulated zoledronic acid results in decreased expression of VANGL1 mRNA 1p13.1 Zoledronic acid Approved VARS 7407 upregulated zoledronic acid results in increased expression of VARS mRNA 6p21.33 Zoledronic acid Approved VASH1 22846 upregulated zoledronic acid results in increased expression of VASH1 mRNA 14q24.3 Zoledronic acid Approved VEGFA 7422 upregulated zoledronic acid results in increased expression of VEGFA mRNA 6p21.1 Zoledronic acid Approved WDR1 9948 upregulated zoledronic acid results in increased expression of WDR1 mRNA 4p16.1 Zoledronic acid Approved WDTC1 23038 upregulated zoledronic acid results in increased expression of WDTC1 mRNA 1p36.11 Zoledronic acid Approved WHAMM 123720 upregulated zoledronic acid results in increased expression of WHAMM mRNA 15q25.2 Zoledronic acid Approved WNK1 65125 downregulated zoledronic acid results in decreased expression of WNK1 mRNA 12p13.33 Zoledronic acid Approved YTHDF3 253943 upregulated zoledronic acid results in increased expression of YTHDF3 mRNA 8q12.3 Zoledronic acid Approved ZBTB4 57659 downregulated zoledronic acid results in decreased expression of ZBTB4 mRNA 17p13.1 Zoledronic acid Approved ZC3HAV1 56829 upregulated zoledronic acid results in increased expression of ZC3HAV1 mRNA 7q34 Zoledronic acid Approved ZFP36L2 678 upregulated zoledronic acid results in increased expression of ZFP36L2 mRNA 2p21 Zoledronic acid Approved ZNF146 7705 upregulated zoledronic acid results in increased expression of ZNF146 mRNA 19q13.1 Zoledronic acid Approved ZNF436 80818 upregulated zoledronic acid results in increased expression of ZNF436 mRNA 1p36.12 Zoledronic acid Approved ZNF467 168544 upregulated zoledronic acid results in increased expression of ZNF467 mRNA 7q36.1 Zoledronic acid Approved ZNF485 220992 downregulated zoledronic acid results in decreased expression of ZNF485 mRNA 10q11.21 Zoledronic acid Approved ZNF644 84146 upregulated zoledronic acid results in increased expression of ZNF644 mRNA 1p22.2 Zoledronic acid Approved ZNF74 7625 upregulated zoledronic acid results in increased expression of ZNF74 mRNA 22q11.21 Zoledronic acid Approved ZSCAN25 221785 upregulated zoledronic acid results in increased expression of ZSCAN25 mRNA 7q22.1